

Stem cell concepts renew cancer research

Blood

112, 4793-4807

DOI: [10.1182/blood-2008-08-077941](https://doi.org/10.1182/blood-2008-08-077941)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pathology of Hematopoietic Stem Cell Transplantation. , 0, , 260-293.		0
2	Pluripotent Transcription Factors Possess Distinct Roles in Normal versus Transformed Human Stem Cells. PLoS ONE, 2009, 4, e8065.	1.1	26
3	Modification of mammalian reoviruses for use as oncolytic agents. Expert Opinion on Biological Therapy, 2009, 9, 1509-1520.	1.4	19
4	Place de la biologie moléculaire dans l'évaluation pronostique des patients atteints de leucémie aiguë myéloïde. Hematologie, 2009, 15, 426-443.	0.0	0
5	Tissue Factor and Cancer Stem Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2005-2014.	1.1	40
6	Allotransplantation for chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2009, 2009, 602-609.	0.9	36
7	Malignant stem cells in childhood acute lymphoblastic leukemia: The stem cell concept revisited. Cell Cycle, 2009, 8, 996-999.	1.3	12
8	TGF β^2 and cancer initiating cells. Cell Cycle, 2009, 8, 3787-3788.	1.3	7
9	Genomic instability en route to and from cancer stem cells. Cell Cycle, 2009, 8, 1000-1002.	1.3	36
10	Expression of an Exogenous Human Oct-4 Promoter Identifies Tumor-Initiating Cells in Osteosarcoma. Cancer Research, 2009, 69, 5648-5655.	0.4	153
11	Brain Tumor Stem Cells. Neurochemical Research, 2009, 34, 2055-2066.	1.6	19
12	Vaccination with Human Pluripotent Stem Cells Generates a Broad Spectrum of Immunological and Clinical Responses Against Colon Cancer. Stem Cells, 2009, 27, 3103-3111.	1.4	76
13	Cancer stem cells and their niche. Cancer Science, 2009, 100, 1166-1172.	1.7	125
14	Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Science, 2009, 100, 2275-2282.	1.7	45
15	Looking ahead in cancer stem cell research. Nature Biotechnology, 2009, 27, 44-46.	9.4	193
16	GPS navigation of the protein-stability landscape. Nature Biotechnology, 2009, 27, 46-48.	9.4	2
17	HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Medicine, 2009, 15, 893-900.	15.2	1,519
18	Non-genetic heterogeneity is a mutation-independent driving force for the somatic evolution of tumours. Nature Reviews Genetics, 2009, 10, 336-342.	7.7	455

#	ARTICLE	IF	CITATIONS
19	The Role of PLZF in Human Myeloid Development. <i>Annals of the New York Academy of Sciences</i> , 2009, 1176, 150-153.	1.8	14
20	Neuroblastoma: contemporary management. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2009, 94, 177-185.	0.3	26
21	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13820-13825.	3.3	1,257
22	EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance. <i>Cancer Research</i> , 2009, 69, 9211-9218.	0.4	431
23	Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution. <i>Cell</i> , 2009, 138, 822-829.	13.5	1,036
24	SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma. <i>Cell Stem Cell</i> , 2009, 4, 440-452.	5.2	598
25	Molecular Targeting of Cancer Stem Cells. <i>Cell Stem Cell</i> , 2009, 5, 125-126.	5.2	18
26	Unraveling the Human Embryonic Stem Cell Phosphoproteome. <i>Cell Stem Cell</i> , 2009, 5, 126-128.	5.2	10
27	Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective. <i>Seminars in Cell and Developmental Biology</i> , 2009, 20, 869-876.	2.3	491
28	The Increasing Complexity of the Cancer Stem Cell Paradigm. <i>Science</i> , 2009, 324, 1670-1673.	6.0	630
29	Dendritic cell homeostasis. <i>Blood</i> , 2009, 113, 3418-3427.	0.6	332
30	Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1872-1885.	13.9	614
31	Repair of Tissues by Adult Stem/Progenitor Cells (MSCs): Controversies, Myths, and Changing Paradigms. <i>Molecular Therapy</i> , 2009, 17, 939-946.	3.7	524
32	Biology of Stem Cells and the Molecular Basis of the Stem State. , 2009, , .		18
33	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, xi-xviii.	0.9	1
34	Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. <i>Translational Oncology</i> , 2009, 2, 321-328.	1.7	215
35	Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. <i>Blood</i> , 2009, 114, 3983-3993.	0.6	69
36	Treating autoimmune diseases: is stem cell therapy the future?. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 395-408.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas. <i>Current Stem Cell Research and Therapy</i> , 2010, 5, 63-73.	0.6	35
38	Assessment of minimal residual disease in acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2010, 22, 656-663.	1.1	71
39	Evidence that Growth factor independence 1b regulates dormancy and peripheral blood mobilization of hematopoietic stem cells. <i>Blood</i> , 2010, 116, 5149-5161.	0.6	66
40	Homeostasis of adult human stem cells and carcinogenesis. <i>Human Physiology</i> , 2010, 36, 621-628.	0.1	1
41	Morphological and functional heterogeneity of Zajdela rat ascites hepatoma cells. <i>Cell and Tissue Biology</i> , 2010, 4, 500-510.	0.2	1
43	Breast cancer stem cells. <i>Breast Cancer</i> , 2010, 17, 80-85.	1.3	76
44	The Hemopoietic Stem Cell Niche Versus the Microenvironment of the Multiple Myeloma-Tumor Initiating Cell. <i>Cancer Microenvironment</i> , 2010, 3, 15-28.	3.1	31
45	Stem Cell Competition for Niche Occupancy: Emerging Themes and Mechanisms. <i>Stem Cell Reviews and Reports</i> , 2010, 6, 345-350.	5.6	12
46	Do nutraceuticals play a role in the prevention and treatment of colorectal cancer?. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 395-404.	2.7	23
47	Cancer stem cells: Back to Darwin?. <i>Seminars in Cancer Biology</i> , 2010, 20, 65-70.	4.3	123
48	Normal stem cells and cancer stem cells: similar and different. <i>Seminars in Cancer Biology</i> , 2010, 20, 85-92.	4.3	127
49	Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?. <i>Seminars in Cancer Biology</i> , 2010, 20, 178-185.	4.3	54
50	Tumor heterogeneity: Causes and consequences. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1805, 105-117.	3.3	1,036
51	PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas. <i>Cancer Cell</i> , 2010, 17, 497-509.	7.7	224
52	TGF- β 2 Receptor Inhibitors Target the CD44 ^{high} /Id1 ^{high} Glioma-Initiating Cell Population in Human Glioblastoma. <i>Cancer Cell</i> , 2010, 18, 655-668.	7.7	534
53	Cancer stem cells: A stride towards cancer cure?. <i>Journal of Cellular Physiology</i> , 2010, 225, 7-14.	2.0	57
54	The evolution of tumor metastases during clonal expansion. <i>Journal of Theoretical Biology</i> , 2010, 263, 30-44.	0.8	37
55	FLT3/internal tandem duplication subclones in acute myeloid leukemia differ in their engraftment potential in NOD/SCID mice. <i>Leukemia Research</i> , 2010, 34, 119-122.	0.4	10

#	ARTICLE	IF	CITATIONS
56	High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2010, 34, 1139-1142.	0.4	25
57	CD34+/CD38 ^{low} cells and minimal residual disease in childhood lymphoblastic leukemia. <i>Leukemia Research</i> , 2010, 34, 1125-1126.	0.4	6
58	Population genetics of cancer cell clones: possible implications of cancer stem cells. <i>Theoretical Biology and Medical Modelling</i> , 2010, 7, 42.	2.1	11
59	Permanently Blocked Stem Cells Derived From Breast Cancer Cell Lines. <i>Stem Cells</i> , 2010, 28, 1008-1018.	1.4	47
60	A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. <i>British Journal of Haematology</i> , 2010, 150, 574-586.	1.2	115
61	Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. <i>Oncogene</i> , 2010, 29, 6115-6124.	2.6	83
62	Understanding the cancer stem cell. <i>British Journal of Cancer</i> , 2010, 103, 439-445.	2.9	181
63	Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. <i>Leukemia</i> , 2010, 24, 1751-1759.	3.3	39
64	Functional differences between myeloid leukemia-initiating and transient leukemia cells in Down's syndrome. <i>Leukemia</i> , 2010, 24, 1012-1017.	3.3	11
65	Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. <i>Nature Immunology</i> , 2010, 11, 585-593.	7.0	430
66	Nucleoside Drugs Induce Cellular Differentiation by Caspase-Dependent Degradation of Stem Cell Factors. <i>PLoS ONE</i> , 2010, 5, e10726.	1.1	38
67	Tumorigenic WAP-T Mouse Mammary Carcinoma Cells: A Model for a Self-Reproducing Homeostatic Cancer Cell System. <i>PLoS ONE</i> , 2010, 5, e12103.	1.1	21
68	Identification of Hematopoietic Stem Cell-Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy. <i>Science Translational Medicine</i> , 2010, 2, 58ra84.	5.8	180
69	Deficiency in p53 but not Retinoblastoma Induces the Transformation of Mesenchymal Stem Cells <i>In vitro</i> and Initiates Leiomyosarcoma <i>In vivo</i> . <i>Cancer Research</i> , 2010, 70, 4185-4194.	0.4	96
70	New hope in the horizon: cancer stems cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2010, 42, 237-242.	0.9	17
71	Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. <i>Journal of Experimental Medicine</i> , 2010, 207, 2785-2792.	4.2	85
72	Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16280-16285.	3.3	147
73	Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. <i>Journal of Clinical Investigation</i> , 2010, 120, 636-644.	3.9	299

#	ARTICLE	IF	CITATIONS
74	Bone Marrow Stromal Cells From Myeloma Patients Support the Growth of Myeloma Stem Cells. <i>Stem Cells and Development</i> , 2010, 19, 1289-1296.	1.1	35
75	The vent-like homeobox gene <i>VENTX</i> promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16946-16951.	3.3	25
76	Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. <i>Carcinogenesis</i> , 2010, 31, 1376-1380.	1.3	103
77	A Quest for Initiating Cells of Head and Neck Cancer and Their Treatment. <i>Cancers</i> , 2010, 2, 1528-1554.	1.7	3
78	Pig-a Mutation: Kinetics in Rat Erythrocytes Following Exposure to Five Prototypical Mutagens. <i>Toxicological Sciences</i> , 2010, 114, 59-70.	1.4	84
79	Epidermal Growth Factor Receptor Expression Identifies Functionally and Molecularly Distinct Tumor-Initiating Cells in Human Glioblastoma Multiforme and Is Required for Gliomagenesis. <i>Cancer Research</i> , 2010, 70, 7500-7513.	0.4	198
81	Suicide gene therapy for graft-versus-host disease. <i>Immunotherapy</i> , 2010, 2, 521-537.	1.0	5
82	Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1159-1173.	2.4	32
83	Cancer-Initiating Cells in Colorectal Cancer. <i>Cancer Metastasis - Biology and Treatment</i> , 2010, , 127-146.	0.1	1
84	Targeting leukemic stem cells by breaking their dormancy. <i>Molecular Oncology</i> , 2010, 4, 443-450.	2.1	171
85	Progress in understanding melanoma propagation. <i>Molecular Oncology</i> , 2010, 4, 451-457.	2.1	31
86	Knock down of HIF-1 α in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. <i>Molecular Cancer</i> , 2010, 9, 133.	7.9	175
87	The Wnt/ β -catenin pathway regulates growth and maintenance of colonospheres. <i>Molecular Cancer</i> , 2010, 9, 212.	7.9	218
88	Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. <i>Nature Biotechnology</i> , 2010, 28, 275-280.	9.4	373
89	The therapeutic potential of stem cells. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2010, 365, 155-163.	1.8	145
90	Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2706.	3.8	339
91	Apoptosis signaling in cancer stem cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 31-38.	1.2	67
92	Inflammatory signaling pathways in self-renewing breast cancer stem cells. <i>Current Opinion in Pharmacology</i> , 2010, 10, 650-654.	1.7	24

#	ARTICLE	IF	CITATIONS
93	β1,4-Galactosyltransferase V regulates self-renewal of glioma-initiating cell. <i>Biochemical and Biophysical Research Communications</i> , 2010, 396, 602-607.	1.0	16
94	Sox2 is translationally activated by eukaryotic initiation factor 4E in human glioma-initiating cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 397, 711-717.	1.0	34
95	A Distinctive DNA Damage Response in Human Hematopoietic Stem Cells Reveals an Apoptosis-Independent Role for p53 in Self-Renewal. <i>Cell Stem Cell</i> , 2010, 7, 186-197.	5.2	243
96	EGFR signaling in breast cancer: Bad to the bone. <i>Seminars in Cell and Developmental Biology</i> , 2010, 21, 951-960.	2.3	129
97	Role of the tissue factor pathway in the biology of tumor initiating cells. <i>Thrombosis Research</i> , 2010, 125, S44-S50.	0.8	38
98	Asymmetric Distribution of Epidermal Growth Factor Receptor Directs the Fate of Normal and Cancer Keratinocytes In Vitro. <i>Stem Cells and Development</i> , 2010, 19, 209-220.	1.1	22
99	Epigenetic Codes in Stem Cells and Cancer Stem Cells. <i>Advances in Genetics</i> , 2010, 70, 177-199.	0.8	14
100	Targeting breast cancer stem cells. <i>Molecular Oncology</i> , 2010, 4, 404-419.	2.1	170
101	The Wnt/β2-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML. <i>Science</i> , 2010, 327, 1650-1653.	6.0	675
103	Cellular heterogeneity and live cell arrays. <i>Chemical Society Reviews</i> , 2011, 40, 4049.	18.7	92
104	Cell Surface Marker Phenotypes and Gene Expression Profiles of Murine Radiation-Induced Acute Myeloid Leukemia Stem Cells are Similar to Those of Common Myeloid Progenitors. <i>Radiation Research</i> , 2011, 176, 311-322.	0.7	20
105	Targeting ALDHbright Human Carcinoma-Initiating Cells with ALDH1A1-Specific CD8+ T Cells. <i>Clinical Cancer Research</i> , 2011, 17, 6174-6184.	3.2	148
106	Tumor vaccines and beyond. <i>Cytotherapy</i> , 2011, 13, 8-18.	0.3	9
108	Fluorescent Imaging of Cancer in Zebrafish. <i>Methods in Cell Biology</i> , 2011, 105, 437-459.	0.5	26
109	Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 623-642.	1.5	108
110	Stem cell gene expression programs influence clinical outcome in human leukemia. <i>Nature Medicine</i> , 2011, 17, 1086-1093.	15.2	894
111	Hurdles Toward a Cure for CML: The CML Stem Cell. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 951-966.	0.9	23
112	Linking Stem Cells to Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 610-613.	1.8	33

#	ARTICLE	IF	CITATIONS
114	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. <i>Nature</i> , 2011, 478, 524-528.	13.7	1,656
116	Lymph Node Stromal Cells Enhance Drug-Resistant Colon Cancer Cell Tumor Formation through SDF-1 α /CXCR4 Paracrine Signaling. <i>Neoplasia</i> , 2011, 13, 874-IN30.	2.3	59
117	Culture Adaptation of Pluripotent Stem Cells: Challenges and Opportunities. , 2011, , 265-276.		0
118	Intratumor Heterogeneity in Evolutionary Models of Tumor Progression. <i>Genetics</i> , 2011, 188, 461-477.	1.2	118
119	Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 97-106.	12.5	870
120	Functional Crosstalk between Bmi1 and MLL/Hoxa9 Axis in Establishment of Normal Hematopoietic and Leukemic Stem Cells. <i>Cell Stem Cell</i> , 2011, 8, 649-662.	5.2	113
121	p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 1739-1750.	3.3	64
122	Cancer stem cells: the development of new cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 875-892.	1.4	34
123	A Tumor-Related Lymphoid Progenitor Population Supports Hierarchical Tumor Organization in Canine B-Cell Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2011, 25, 890-896.	0.6	25
124	High Proportion of Leukemic Stem Cells at Diagnosis Is Correlated with Unfavorable Prognosis in Childhood Acute Myeloid Leukemia. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 91-99.	0.3	43
125	Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells. <i>Molecular Medicine</i> , 2011, 17, 1374-1382.	1.9	140
126	p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. <i>Nature Precedings</i> , 2011, , .	0.1	1
127	Connections between Genomic Instability and Cancer Stem Cells. , 0, , .		0
128	Childhood Acute Leukemias in Hispanic Population: Differences by Age Peak and Immunophenotype. , 2011, , .		3
129	Structure and Function of Hematopoietic Organs. , 2011, , 1131-1139.		0
130	Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 368.	3.0	49
131	ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. <i>PLoS ONE</i> , 2011, 6, e20636.	1.1	241
132	TGF- β 2 Signaling in High-Grade Gliomas. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 2150-2157.	0.9	52

#	ARTICLE	IF	CITATIONS
133	Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 469-487.	0.9	9
134	Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. <i>Blood</i> , 2011, 117, 1781-1791.	0.6	230
135	Cancer stem cells and markers: New model of tumorigenesis with therapeutic implications. <i>Cancer Biomarkers</i> , 2011, 9, 65-99.	0.8	13
136	The cancer stem cell: premises, promises and challenges. <i>Nature Medicine</i> , 2011, 17, 313-319.	15.2	1,691
137	RGB marking facilitates multicolor clonal cell tracking. <i>Nature Medicine</i> , 2011, 17, 504-509.	15.2	134
138	Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. <i>Oncogene</i> , 2011, 30, 1009-1019.	2.6	149
139	Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 1423-1432.	3.3	47
140	Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis. <i>Leukemia</i> , 2011, 25, 1213-1216.	3.3	19
141	Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. <i>Leukemia</i> , 2011, 25, 1249-1258.	3.3	58
142	Genetic variegation of clonal architecture and propagating cells in leukaemia. <i>Nature</i> , 2011, 469, 356-361.	13.7	734
143	Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. <i>Nature</i> , 2011, 469, 362-367.	13.7	421
144	Mapping the stem cell state: eight novel human embryonic stem and embryonal carcinoma cell antibodies. <i>Journal of Developmental and Physical Disabilities</i> , 2011, 34, e175-87; discussion e187-8.	3.6	10
145	On the intrinsic inevitability of cancer: From foetal to fatal attraction. <i>Seminars in Cancer Biology</i> , 2011, 21, 183-199.	4.3	73
146	Mathematical Approach to Predict the Drug Effects on Cancer Stem Cell Models. <i>Electronic Notes in Theoretical Computer Science</i> , 2011, 277, 29-39.	0.9	4
147	Nonviral transfection of leukemic primary cells and cells lines by siRNA—a direct comparison between Nucleofection and Accell delivery. <i>Experimental Hematology</i> , 2011, 39, 1081-1089.	0.2	15
148	Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2011, 19, 138-152.	7.7	545
149	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. <i>Cancer Cell</i> , 2011, 20, 25-38.	7.7	792
150	Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. <i>Nature Biotechnology</i> , 2011, 29, 928-933.	9.4	377

#	ARTICLE	IF	CITATIONS
151	DNA repair: the culprit for tumor-initiating cell survival?. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 185-197.	2.7	38
152	PTEN status is related to cell proliferation and self-renewal independent of CD133 phenotype in the glioma-initiating cells. <i>Molecular and Cellular Biochemistry</i> , 2011, 349, 149-157.	1.4	11
153	Pancreatic cancer stem cell biology and its therapeutic implications. <i>Journal of Gastroenterology</i> , 2011, 46, 1345-1352.	2.3	26
154	Leukemia stem cells. <i>Annals of Hematology</i> , 2011, 90, 245-271.	0.8	46
155	Stochastic acquisition of a stem cell-like state and drug tolerance in leukemia cells stressed by radiation. <i>International Journal of Hematology</i> , 2011, 93, 27-35.	0.7	14
156	Can metabolic plasticity be a cause for cancer? Warburg's "Waddington legacy revisited. <i>Clinical Epigenetics</i> , 2011, 2, 113-122.	1.8	12
157	Antitumor activity of erythromycin on human neuroblastoma cell line (SH-SY5Y). <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2011, 31, 33-38.	1.0	3
158	Î³-Secretase inhibitor, DAPT inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2011, 23, 140-146.	0.7	37
159	Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. <i>Journal of Molecular Signaling</i> , 2011, 6, 7.	0.5	122
160	Pluripotent stem cell heterogeneity and the evolving role of proteomic technologies in stem cell biology. <i>Proteomics</i> , 2011, 11, 3947-3961.	1.3	20
161	Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological Barriers. <i>Advanced Materials</i> , 2011, 23, H217-47.	11.1	432
162	SPOC1 (PHF13) is required for spermatogonial stem cell differentiation and sustained spermatogenesis. <i>Journal of Cell Science</i> , 2011, 124, 3137-3148.	1.2	25
163	Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells. <i>Current Medicinal Chemistry</i> , 2011, 18, 2715-2726.	1.2	109
165	Cancer Stem Cells in Ulcerative Colitis. <i>Onkologie</i> , 2011, 34, 660-662.	1.1	0
166	Cancer stem cells renew their impact. <i>Nature Medicine</i> , 2011, 17, 1046-1048.	15.2	18
167	Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. <i>Journal of Experimental Medicine</i> , 2011, 208, 653-661.	4.2	175
168	Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-Î²B signalling. <i>Nature Communications</i> , 2011, 2, 162.	5.8	239
169	Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. <i>Journal of Biomedical Optics</i> , 2011, 16, 011006.	1.4	39

#	ARTICLE	IF	CITATIONS
170	Pathways Implicated in Stem Cell Migration: The SDF-1/CXCR4 Axis. <i>Methods in Molecular Biology</i> , 2011, 750, 277-289.	0.4	55
171	Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5009-5014.	3.3	248
172	Converging histories, reconsidered potentialities: The stem cell and cancer. <i>BioSocieties</i> , 2011, 6, 195-216.	0.8	4
173	Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G347-G355.	1.6	28
174	Stem Cell Quiescence. <i>Clinical Cancer Research</i> , 2011, 17, 4936-4941.	3.2	251
175	A Novel Gemini Vitamin D Analog Represses the Expression of a Stem Cell Marker CD44 in Breast Cancer. <i>Molecular Pharmacology</i> , 2011, 79, 360-367.	1.0	81
176	Immunophenotype-defined sub-populations are common at diagnosis in childhood B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2011, 25, 1652-1657.	3.3	10
177	<i>Cancer Systems Biology</i> , 2011, , 533-565.		1
178	Colorectal Cancer Stem Cells and Cell Death. <i>Cancers</i> , 2011, 3, 1929-1946.	1.7	15
179	Salinomycin as a Drug for Targeting Human Cancer Stem Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-17.	3.0	274
180	Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. <i>Cancers</i> , 2012, 4, 904-944.	1.7	34
181	Targeting cancer stem cells with ALDH1A1-based immunotherapy. <i>Oncolmmunology</i> , 2012, 1, 385-387.	2.1	7
183	The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. <i>Nucleic Acids Research</i> , 2012, 40, D984-D991.	6.5	29
184	Promises and challenges of exhausting pediatric neural cancer stem cells. <i>Pediatric Research</i> , 2012, 71, 523-528.	1.1	6
185	A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. <i>MAbs</i> , 2012, 4, 45-56.	2.6	24
187	CD133 as a target for colon cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 259-267.	1.5	30
188	Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia. <i>Oncogenesis</i> , 2012, 1, e19-e19.	2.1	33
189	<i>Advances in Cancer Stem Cell Biology</i> , 2012, , .		3

#	ARTICLE	IF	CITATIONS
190	Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. <i>Scientific Reports</i> , 2012, 2, 516.	1.6	85
191	A microRNA Link to Glioblastoma Heterogeneity. <i>Cancers</i> , 2012, 4, 846-872.	1.7	15
192	Association of Promyelocytic Leukemia Protein with Expression of IL-6 and Resistance to Treatment in Multiple Myeloma. <i>Acta Haematologica</i> , 2012, 128, 213-222.	0.7	5
193	Skin-Derived Precursor Cells as an In Vitro Modelling Tool for the Study of Type 1 Neurofibromatosis. <i>Stem Cells International</i> , 2012, 2012, 1-9.	1.2	3
194	Targeting Cancer Stem Cells with Natural Products. <i>Current Drug Targets</i> , 2012, 13, 1054-1064.	1.0	29
195	shRNA targeting Bmi1 impedes the self-renewal of cisplatin-enriched stem-like cells in human A549 cells. <i>Oncology Reports</i> , 2012, 28, 629-639.	1.2	5
196	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. <i>Blood</i> , 2012, 119, 6198-6208.	0.6	273
197	Role of stemness-related molecules in neuroblastoma. <i>Pediatric Research</i> , 2012, 71, 511-515.	1.1	39
198	Regulation of self-renewal in normal and cancer stem cells. <i>FEBS Journal</i> , 2012, 279, 3559-3572.	2.2	44
199	<scp>EGF</scp> signalling pathway regulates colon cancer stem cell proliferation and apoptosis. <i>Cell Proliferation</i> , 2012, 45, 413-419.	2.4	66
200	A Simple Mathematical Model Based on the Cancer Stem Cell Hypothesis Suggests Kinetic Commonalities in Solid Tumor Growth. <i>PLoS ONE</i> , 2012, 7, e26233.	1.1	52
201	Hematopoiesis. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a008250-a008250.	2.3	133
202	Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain. <i>Blood</i> , 2012, 119, 1848-1855.	0.6	46
203	Stem Cell and Benzene-Induced Malignancy and Hematotoxicity. <i>Chemical Research in Toxicology</i> , 2012, 25, 1303-1315.	1.7	64
204	Decoupling of Tumor-Initiating Activity from Stable Immunophenotype in HoxA9-Meis1-Driven AML. <i>Cell Stem Cell</i> , 2012, 10, 210-217.	5.2	55
205	Hematopoiesis: A Human Perspective. <i>Cell Stem Cell</i> , 2012, 10, 120-136.	5.2	679
206	Use of rHuG-CSF for the Treatment of Myeloid Leukemia and in Targeting Leukemia Stem Cells. , 2012, , 169-182.		0
207	Nasopharyngeal Carcinoma: Investigation of Intratumoral Heterogeneity With FDG PET/CT. <i>American Journal of Roentgenology</i> , 2012, 199, 169-174.	1.0	48

#	ARTICLE	IF	CITATIONS
208	Mobilization of hematopoietic stem and leukemia cells. <i>Journal of Leukocyte Biology</i> , 2011, 91, 47-57.	1.5	34
209	The evolving concept of cancer and metastasis stem cells. <i>Journal of Cell Biology</i> , 2012, 198, 281-293.	2.3	356
210	Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. <i>Cancer Letters</i> , 2012, 323, 161-170.	3.2	83
211	Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State. <i>Cell</i> , 2012, 148, 1015-1028.	13.5	830
212	Role of leucine-rich pentatricopeptide repeat motif-containing protein (LRPPRC) for anti-apoptosis and tumorigenesis in cancers. <i>European Journal of Cancer</i> , 2012, 48, 2462-2473.	1.3	44
213	The emerging role of histone lysine demethylases in prostate cancer. <i>Molecular Cancer</i> , 2012, 11, 52.	7.9	72
214	Tumor heterogeneity and its implication for drug delivery. <i>Journal of Controlled Release</i> , 2012, 164, 187-191.	4.8	117
215	Tumor progression: Chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. <i>Progress in Biophysics and Molecular Biology</i> , 2012, 110, 69-86.	1.4	61
217	Cancer Stem Cells of the Head and Neck. <i>Stem Cells and Cancer Stem Cells</i> , 2012, , 275-286.	0.1	0
218	The Notch Pathway in Hematopoietic Stem Cells. <i>Current Topics in Microbiology and Immunology</i> , 2012, 360, 1-18.	0.7	31
219	Nuclear Reprogramming and Stem Cells. , 2012, , .		1
221	Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 1784-1795.	0.9	39
222	Cancer Stem Cell. , 2012, , 173-196.		1
223	Establishment and Characterization of a Highly Tumorigenic and Cancer Stem Cell Enriched Pancreatic Cancer Cell Line as a Well Defined Model System. <i>PLoS ONE</i> , 2012, 7, e48503.	1.1	33
224	In Vivo Imaging Enables High Resolution Preclinical Trials on Patientsâ€™ Leukemia Cells Growing in Mice. <i>PLoS ONE</i> , 2012, 7, e52798.	1.1	39
225	On the Nature of the Tumor-Initiating Cell. <i>Current Stem Cell Research and Therapy</i> , 2012, 7, 26-35.	0.6	15
226	The role of cancer stem cells in relapse of solid tumors. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1528.	0.9	75
227	Current Strategies for Identification of Glioma Stem Cells: Adequate or Unsatisfactory?. <i>Journal of Oncology</i> , 2012, 2012, 1-10.	0.6	75

#	ARTICLE	IF	CITATIONS
228	Role of the Wnt Pathway in Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 31.	1.5	103
229	The role of cancer stem cells in relapse of solid tumors. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1528-1541.	0.9	117
230	Adult Stem Cells in Tissue Homeostasis and Disease. , 2012, , .		2
231	From HSC to B-Lymphoid Cells in Normal and Malignant Hematopoiesis. , 2012, , .		5
232	In vitro models. <i>Stem Cells</i> , 2012, 30, 95-99.	1.4	31
233	Protein cross-talk in <i>CD133+</i> colon cancer cells indicates activation of the <i>Wnt</i> pathway and upregulation of <i>SRp20</i> that is potentially involved in tumorigenicity. <i>Proteomics</i> , 2012, 12, 2045-2059.	1.3	52
234	Identification of Drugs Including Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells. <i>Cell</i> , 2012, 149, 1284-1297.	13.5	420
235	Cancer stem cells, microRNAs, and therapeutic strategies including natural products. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 733-751.	2.7	58
236	The <i>MET</i> Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype. <i>Cancer Research</i> , 2012, 72, 4537-4550.	0.4	120
237	Cancer stem cells and their potential implications for the treatment of solid tumors. <i>Journal of Surgical Oncology</i> , 2012, 106, 209-215.	0.8	36
238	Insights on neoplastic stem cells from gel-based proteomics of childhood germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2012, 58, 722-728.	0.8	8
239	Diverging fates of cells of origin in acute and chronic leukaemia. <i>EMBO Molecular Medicine</i> , 2012, 4, 283-297.	3.3	22
240	Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. <i>Blood</i> , 2012, 120, 603-612.	0.6	67
241	Clonal evolution in cancer. <i>Nature</i> , 2012, 481, 306-313.	13.7	2,570
242	Roles of the hypoxia response system in hematopoietic and leukemic stem cells. <i>International Journal of Hematology</i> , 2012, 95, 478-483.	0.7	39
243	Tumorigenic Cells Are Common in Mouse MPNSTs but Their Frequency Depends upon Tumor Genotype and Assay Conditions. <i>Cancer Cell</i> , 2012, 21, 240-252.	7.7	29
244	Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty. <i>Cancer Cell</i> , 2012, 21, 283-296.	7.7	999
245	ID1 and ID3 Regulate the Self-Renewal Capacity of Human Colon Cancer-Initiating Cells through p21. <i>Cancer Cell</i> , 2012, 21, 777-792.	7.7	193

#	ARTICLE	IF	CITATIONS
246	Early Lymphoid Development and Microenvironmental Cues in B-cell Acute Lymphoblastic Leukemia. Archives of Medical Research, 2012, 43, 89-101.	1.5	37
247	Stem cells in squamous head and neck cancer. Critical Reviews in Oncology/Hematology, 2012, 81, 224-240.	2.0	55
248	p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies. Seminars in Oncology, 2012, 39, 97-108.	0.8	51
249	Piwi and piwi-interacting RNAs in the epigenetics of cancer. Journal of Cellular Biochemistry, 2012, 113, 373-380.	1.2	143
250	Cancer heterogeneity—a multifaceted view. EMBO Reports, 2013, 14, 686-695.	2.0	208
251	SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias. Leukemia and Lymphoma, 2013, 54, 1488-1499.	0.6	10
253	Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. Immunotherapy, 2013, 5, 859-868.	1.0	8
255	Novel Hypothesis on Telomere Length: Heterogenic Targets as Genomic/Somatic Diverse Value in Breast Cancer and Brain Tumor. , 2013, , 99-141.		0
256	Cancer Stem Cells: Prospective Isolation and Progress Toward Functional Biomarker Identification. Current Pathobiology Reports, 2013, 1, 81-90.	1.6	0
257	Animal Models of Cancer Stem Cells: What are They Really Telling Us?. Current Pathobiology Reports, 2013, 1, 91-99.	1.6	8
258	Regulation of apoptosis pathways in cancer stem cells. Cancer Letters, 2013, 338, 168-173.	3.2	56
259	An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia, 2013, 27, 1441-1450.	3.3	81
261	LIN28/LIN28B: An emerging oncogenic driver in cancer stem cells. International Journal of Biochemistry and Cell Biology, 2013, 45, 973-978.	1.2	140
262	NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2. Journal of Translational Medicine, 2013, 11, 289.	1.8	12
263	Lack of the p42 form of C/EBP β leads to spontaneous immortalization and lineage infidelity of committed myeloid progenitors. Experimental Hematology, 2013, 41, 882-893.e16.	0.2	8
264	Tumour heterogeneity and cancer cell plasticity. Nature, 2013, 501, 328-337.	13.7	2,043
265	Systems Biology of Tumor Dormancy. Advances in Experimental Medicine and Biology, 2013, , .	0.8	9
266	Tumor Dormancy, Oncogene Addiction, Cellular Senescence, and Self-Renewal Programs. Advances in Experimental Medicine and Biology, 2013, 734, 91-107.	0.8	36

#	ARTICLE	IF	CITATIONS
267	Multiple drug resistant, tumorigenic stem-like cells in oral cancer. <i>Cancer Letters</i> , 2013, 338, 300-316.	3.2	26
268	Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma. <i>Cancer Letters</i> , 2013, 330, 181-189.	3.2	70
269	Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2013, 27, 2289-2300.	3.3	48
270	Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer. <i>Science</i> , 2013, 339, 543-548.	6.0	691
271	Cellular Heterogeneity and Molecular Evolution in Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2013, 8, 277-302.	9.6	420
272	Renal stem cells and their implications for kidney cancer. <i>Seminars in Cancer Biology</i> , 2013, 23, 56-61.	4.3	30
273	Acute B lymphoblastic leukaemiaâ€propagating cells are present at high frequency in diverse lymphoblast populations. <i>EMBO Molecular Medicine</i> , 2013, 5, 38-51.	3.3	80
274	Complexity of cancer stem cells. <i>International Journal of Cancer</i> , 2013, 132, 1249-1259.	2.3	109
275	CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. <i>Journal of Pathology</i> , 2013, 229, 355-378.	2.1	252
276	TGF-Î²-Id1 Signaling Opposes Twist1 and Promotes Metastatic Colonization via a Mesenchymal-to-Epithelial Transition. <i>Cell Reports</i> , 2013, 5, 1228-1242.	2.9	205
277	Marker-independent Method for Isolating Slow-Dividing Cancer Stem Cells in Human Glioblastoma. <i>Neoplasia</i> , 2013, 15, 840-IN39.	2.3	39
278	Lin28a is a putative factor in regulating cancer stem cell-like properties in side population cells of oral squamous cell carcinoma. <i>Experimental Cell Research</i> , 2013, 319, 1220-1228.	1.2	19
279	Colon cancer stem cells â€œ From basic to clinical application. <i>Cancer Letters</i> , 2013, 338, 127-140.	3.2	51
280	Putative cancer stem cell marker expression in oral epithelial dysplasia and squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2013, 42, 755-760.	1.4	34
281	Possible carcinogenesis of tumor suppressor let-7. <i>Medical Hypotheses</i> , 2013, 81, 410-413.	0.8	8
282	Melanocytes, melanocyte stem cells, and melanoma stem cells. <i>Clinics in Dermatology</i> , 2013, 31, 166-178.	0.8	60
283	Cancer stem cells as â€œunits of selectionâ€™. <i>Evolutionary Applications</i> , 2013, 6, 102-108.	1.5	66
284	Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery. <i>Drug Delivery and Translational Research</i> , 2013, 3, 121-142.	3.0	15

#	ARTICLE	IF	CITATIONS
285	Diagnosis and Treatment of Childhood Acute Myeloid Leukemia. , 2013, , 355-373.		1
286	Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1. Cancer Cell, 2013, 23, 171-185.	7.7	390
287	Biological rationale for the design of polymeric anti-cancer nanomedicines. Journal of Drug Targeting, 2013, 21, 1-26.	2.1	63
288	Solute carriers (SLCs) in cancer. Molecular Aspects of Medicine, 2013, 34, 719-734.	2.7	63
289	New Horizons in the Diagnosis, Treatment, and Prevention of Penile Cancer. , 2013, , 143-155.		0
290	Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells. Stem Cell Research, 2013, 11, 601-610.	0.3	68
291	The Functional Role of DAB2IP, a Homeostatic Factor, in Prostate Cancer. , 2013, , 275-293.		1
292	Human Hemato-Lymphoid System Mice: Current Use and Future Potential for Medicine. Annual Review of Immunology, 2013, 31, 635-674.	9.5	304
294	Disruption of Mitochondrial Complexes in Cancer Stem Cells Through Nano-based Drug Delivery: A Promising Mitochondrial Medicine. Cell Biochemistry and Biophysics, 2013, 67, 1075-1079.	0.9	6
295	EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme. Cancer Cell, 2013, 23, 238-248.	7.7	193
296	Tumour heterogeneity and immune-modulation. Current Opinion in Pharmacology, 2013, 13, 497-503.	1.7	37
297	A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. Carcinogenesis, 2013, 34, 2292-2299.	1.3	34
298	JNK Signaling in the Control of the Tumor-Initiating Capacity Associated with Cancer Stem Cells. Genes and Cancer, 2013, 4, 388-396.	0.6	44
299	Aberrant DNA Methylation at Genes Associated with a Stem Cell-like Phenotype in Cholangiocarcinoma Tumors. Cancer Prevention Research, 2013, 6, 1348-1355.	0.7	24
300	Side Population Cells as Prototype of Chemoresistant, Tumor-Initiating Cells. BioMed Research International, 2013, 2013, 1-8.	0.9	66
301	Molecular Research in Penile Cancerâ€”Lessons Learned from the Past and Bright Horizons of the Future?. International Journal of Molecular Sciences, 2013, 14, 19494-19505.	1.8	15
303	Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine. Journal of Leukemia (Los Angeles, Calif), 2013, 01, 1000124.	0.1	21
304	Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an <scp>AML</scp> 1â€•<scp>ETO</scp> mouse model. EMBO Molecular Medicine, 2013, 5, 1804-1820.	3.3	33

#	ARTICLE	IF	CITATIONS
305	Cancer Chemoprevention by Traditional Chinese Herbal Medicine and Dietary Phytochemicals: Targeting Nrf2-Mediated Oxidative Stress/Anti-Inflammatory Responses, Epigenetics, and Cancer Stem Cells. <i>Journal of Traditional and Complementary Medicine</i> , 2013, 3, 69-79.	1.5	35
306	Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia. <i>Blood</i> , 2013, 121, 1384-1393.	0.6	46
307	CD44+ gastric cancer cells with stemness properties are chemoradioresistant and highly invasive. <i>Oncology Letters</i> , 2013, 5, 1793-1798.	0.8	30
308	On a mathematical model of tumor growth based on cancer stem cells. <i>Mathematical Biosciences and Engineering</i> , 2013, 10, 263-278.	1.0	11
310	Let-7: A regulator of the ERK signaling pathway in human breast tumors and breast cancer stem cells. <i>Oncology Reports</i> , 2013, 29, 2079-2087.	1.2	59
311	A Mechanism Linking Id2-TGF β Crosstalk to Reversible Adaptive Plasticity in Neuroblastoma. <i>PLoS ONE</i> , 2013, 8, e83521.	1.1	21
312	Embryonic Stem Cells Markers SOX2, OCT4 and Nanog Expression and Their Correlations with Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2013, 8, e56324.	1.1	149
313	A Small Molecule (Pluripotin) as a Tool for Studying Cancer Stem Cell Biology: Proof of Concept. <i>PLoS ONE</i> , 2013, 8, e57099.	1.1	9
314	Single Unpurified Breast Tumor-Initiating Cells from Multiple Mouse Models Efficiently Elicit Tumors in Immune-Competent Hosts. <i>PLoS ONE</i> , 2013, 8, e58151.	1.1	10
315	In Vivo Expansion of Co-Transplanted T Cells Impacts on Tumor Re-Initiating Activity of Human Acute Myeloid Leukemia in NSG Mice. <i>PLoS ONE</i> , 2013, 8, e60680.	1.1	22
316	CD271 Defines a Stem Cell-Like Population in Hypopharyngeal Cancer. <i>PLoS ONE</i> , 2013, 8, e62002.	1.1	51
317	Heterogeneity of Functional Properties of Clone 66 Murine Breast Cancer Cells Expressing Various Stem Cell Phenotypes. <i>PLoS ONE</i> , 2013, 8, e78725.	1.1	11
318	Isolation of Cancer Stem Like Cells from Human Adenosquamous Carcinoma of the Lung Supports a Monoclonal Origin from a Multipotential Tissue Stem Cell. <i>PLoS ONE</i> , 2013, 8, e79456.	1.1	15
319	Extracellular Vesicles – Biomarkers and Effectors of the Cellular Interactome in Cancer. <i>Frontiers in Pharmacology</i> , 2013, 4, 21.	1.6	161
320	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 1311.	3.0	55
321	Lymphoid Progenitor Cells from Childhood Acute Lymphoblastic Leukemia Are Functionally Deficient and Express High Levels of the Transcriptional Repressor Gfi-1. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-12.	3.3	13
322	Dynamics between Cancer Cell Subpopulations Reveals a Model Coordinating with Both Hierarchical and Stochastic Concepts. <i>PLoS ONE</i> , 2014, 9, e84654.	1.1	45
323	Curcumin Chemosensitizes 5-Fluorouracil Resistant MMR-Deficient Human Colon Cancer Cells in High Density Cultures. <i>PLoS ONE</i> , 2014, 9, e85397.	1.1	103

#	ARTICLE	IF	CITATIONS
324	Establishment of a Humanized APL Model via the Transplantation of PML-RARA-Transduced Human Common Myeloid Progenitors into Immunodeficient Mice. <i>PLoS ONE</i> , 2014, 9, e111082.	1.1	9
326	CD133 is a positive marker for a distinct class of primitive human cord blood-derived CD34-negative hematopoietic stem cells. <i>Leukemia</i> , 2014, 28, 1308-1315.	3.3	71
327	Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. <i>Blood</i> , 2014, 123, 1720-1728.	0.6	97
328	Tumor Clonality: Research and Clinical Aspects. <i>Bulletin of Experimental Biology and Medicine</i> , 2014, 158, 246-251.	0.3	1
329	EGFR controls IQGAP basolateral membrane localization and mitotic spindle orientation during epithelial morphogenesis. <i>EMBO Journal</i> , 2014, 33, 129-145.	3.5	37
330	Cancer Stem Cells: Biological Functions and Therapeutically Targeting. <i>International Journal of Molecular Sciences</i> , 2014, 15, 8169-8185.	1.8	60
331	Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment. <i>Cancers</i> , 2014, 6, 1670-1690.	1.7	1,223
332	Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells. <i>International Journal of Oncology</i> , 2014, 44, 2132-2138.	1.4	23
333	Hitting the bull's eye: targeting HMGA1 in cancer stem cells. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 23-30.	1.1	18
334	Expression of ABCG2 and miR-1 in oral potentially malignant lesions and oral squamous cell carcinoma. <i>Cancer Medicine</i> , 2014, 3, 273-283.	1.3	28
335	PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. <i>Blood</i> , 2014, 124, 1777-1789.	0.6	36
336	Biphasic modulation of cancer stem cell-driven solid tumour dynamics in response to reactivated replicative senescence. <i>Cell Proliferation</i> , 2014, 47, 267-276.	2.4	12
338	CTR2 Identifies a Population of Cancer Cells with Stem Cell-like Features in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 1831-1841.	0.2	35
339	Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes. <i>Medical Oncology</i> , 2014, 31, 293.	1.2	2
340	Cancer stem cells. <i>Anti-Cancer Drugs</i> , 2014, 25, 353-367.	0.7	33
341	Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2014, 9, e107587.	1.1	164
342	Common progenitor cells in mature B-cell malignancies. <i>Current Opinion in Hematology</i> , 2014, 21, 333-340.	1.2	17
343	DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1239-1245.	1.7	51

#	ARTICLE	IF	CITATIONS
344	Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 469-496.	2.7	100
345	Evolution of the Cancer Stem Cell Model. <i>Cell Stem Cell</i> , 2014, 14, 275-291.	5.2	1,825
346	Protein kinase C-delta inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo. <i>BMC Cancer</i> , 2014, 14, 90.	1.1	46
347	Low dose effects of ionizing radiation on normal tissue stem cells. <i>Mutation Research - Reviews in Mutation Research</i> , 2014, 761, 6-14.	2.4	25
348	The paradigm of mutant p53-expressing cancer stem cells and drug resistance. <i>Carcinogenesis</i> , 2014, 35, 1196-1208.	1.3	87
349	The challenge of intratumour heterogeneity in precision medicine. <i>Journal of Internal Medicine</i> , 2014, 276, 41-51.	2.7	66
350	A mesenchymal glioma stem cell profile is related to clinical outcome. <i>Oncogenesis</i> , 2014, 3, e91-e91.	2.1	54
351	Immunology of cancer stem cells in solid tumours. A review. <i>European Journal of Cancer</i> , 2014, 50, 649-655.	1.3	93
352	Targeting cancer stem cells to suppress acquired chemotherapy resistance. <i>Oncogene</i> , 2014, 33, 4451-4463.	2.6	213
353	Self-renewal as a therapeutic target in human colorectal cancer. <i>Nature Medicine</i> , 2014, 20, 29-36.	15.2	438
354	Omega-3 Fatty Acid Is a Potential Preventive Agent for Recurrent Colon Cancer. <i>Cancer Prevention Research</i> , 2014, 7, 1138-1148.	0.7	38
355	Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8595-8600.	3.3	35
356	Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. <i>Haematologica</i> , 2014, 99, 1277-1284.	1.7	98
357	Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. <i>Prostate</i> , 2014, 74, 187-200.	1.2	48
358	CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells. <i>Cancer Research</i> , 2014, 74, 2630-2641.	0.4	176
359	Stem cell markers OCT4 and nestin in laryngeal squamous cell carcinoma and their relation to survivin expression. <i>Pathology Research and Practice</i> , 2014, 210, 751-758.	1.0	12
360	Hierarchy of Breast Cancer Cells: Key to Reverse Dormancy for Therapeutic Intervention. <i>Stem Cells Translational Medicine</i> , 2014, 3, 782-786.	1.6	7
361	Concise Review: Breast Cancer Stem Cells: Regulatory Networks, Stem Cell Niches, and Disease Relevance. <i>Stem Cells Translational Medicine</i> , 2014, 3, 942-948.	1.6	41

#	ARTICLE	IF	CITATIONS
362	Estrogen and its role in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, T273-T283.	1.6	190
363	Human Cancer Growth and Therapy in Immunodeficient Mouse Models. <i>Cold Spring Harbor Protocols</i> , 2014, 2014, pdb.top073585.	0.2	156
365	Therapy Response Correlates with ALDH Activity in ALDH Low-Positive Childhood Acute Lymphoblastic Leukemias. <i>Pediatric Hematology and Oncology</i> , 2014, 31, 303-310.	0.3	2
366	The Nature of Embryonic Stem Cells. <i>Annual Review of Cell and Developmental Biology</i> , 2014, 30, 647-675.	4.0	371
367	Targeting Cancer Stem-like Cells as an Approach to Defeating Cellular Heterogeneity in Ewing Sarcoma. <i>Cancer Research</i> , 2014, 74, 6610-6622.	0.4	28
368	RRAD Promotes EGFR-Mediated STAT3 Activation and Induces Temozolomide Resistance of Malignant Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3049-3061.	1.9	35
369	Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2014, 74, 7048-7059.	0.4	46
370	Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. <i>BMC Cancer</i> , 2014, 14, 585.	1.1	64
371	The Cancer Stem Cell Hypothesis: A Guide to Potential Molecular Targets. <i>Cancer Investigation</i> , 2014, 32, 470-495.	0.6	77
372	Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. <i>Experimental Hematology</i> , 2014, 42, 841-851.	0.2	17
373	Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. <i>Leukemia</i> , 2014, 28, 1969-1977.	3.3	12
374	EZH2: Not EZHY (Easy) to Deal. <i>Molecular Cancer Research</i> , 2014, 12, 639-653.	1.5	92
375	Hypothesis: Tim-3/Galectin-9, A New Pathway for Leukemia Stem Cells Survival by Promoting Expansion of Myeloid-Derived Suppressor Cells and Differentiating into Tumor-Associated Macrophages. <i>Cell Biochemistry and Biophysics</i> , 2014, 70, 273-277.	0.9	49
376	Contribution of the vascular bone marrow niche to leukemia progression. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 198-201.	0.3	1
377	Oncogenic roles of EMT-inducing transcription factors. <i>Nature Cell Biology</i> , 2014, 16, 488-494.	4.6	863
378	Definition of PKC- δ , CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2014, 74, 4822-4835.	0.4	61
379	CD133-Targeted Niche-Dependent Therapy in Cancer. <i>American Journal of Pathology</i> , 2014, 184, 1256-1262.	1.9	15
380	Glial Progenitors as Targets for Transformation in Glioma. <i>Advances in Cancer Research</i> , 2014, 121, 1-65.	1.9	38

#	ARTICLE	IF	CITATIONS
381	Sedimentation field flow fractionation monitoring of in vitro enrichment in cancer stem cells by specific serum-free culture medium. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 963, 40-46.	1.2	11
385	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. <i>Blood</i> , 2014, 123, 3951-3962.	0.6	189
386	Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. <i>Blood</i> , 2014, 124, 96-105.	0.6	24
387	A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population. <i>International Journal of Oncology</i> , 2014, 45, 1857-1866.	1.4	18
388	The crossroads between cancer stem cells and aging. <i>BMC Cancer</i> , 2015, 15, S1.	1.1	17
389	In vitro generation of functional dendritic cells differentiated from CD34 negative cells isolated from human umbilical cord blood. <i>Cell Biology International</i> , 2015, 39, 1080-1086.	1.4	3
390	Prognostic significance of prospectively detected bone marrow micrometastases in esophagogastric cancer: 10-year follow-up confirms prognostic significance. <i>Cancer Medicine</i> , 2015, 4, 1281-1288.	1.3	6
391	Preclinical activity of the novel cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC 209 in acute myeloid leukemia: Implications for leukemia therapy. <i>Cancer Science</i> , 2015, 106, 1705-1713.	1.7	27
392	Xenograft models for normal and malignant stem cells. <i>Blood</i> , 2015, 125, 2630-2640.	0.6	112
393	Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation. <i>Blood</i> , 2015, 126, 1462-1472.	0.6	52
394	Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s2, BCBCR.S29427.	0.6	5
396	Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy. <i>Cancer Cell International</i> , 2015, 15, 96.	1.8	96
397	What Tumor Dynamics Modeling Can Teach us about Exploiting the Stem-Cell View for Better Cancer Treatment. <i>Cancer Informatics</i> , 2015, 14s2, CIN.S17294.	0.9	1
398	A quantitative proteomics analysis of MCF7 breast cancer stem and progenitor cell populations. <i>Proteomics</i> , 2015, 15, 3772-3783.	1.3	23
399	Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. <i>Oncotarget</i> , 2015, 6, 36185-36201.	0.8	34
400	Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2. <i>Biomolecules</i> , 2015, 5, 2854-2876.	1.8	14
401	Hedgehog signaling in cancer stem cells: a focus on hematological cancers. <i>Stem Cells and Cloning: Advances and Applications</i> , 2015, 8, 27.	2.3	41
402	An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging. <i>PLoS ONE</i> , 2015, 10, e0120925.	1.1	78

#	ARTICLE	IF	CITATIONS
403	MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. <i>Theranostics</i> , 2015, 5, 1122-1143.	4.6	664
404	Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target. <i>Oncotarget</i> , 2015, 6, 5490-5500.	0.8	92
405	Kruppel-like factor 4 signals through microRNA-206 to promote tumor initiation and cell survival. <i>Oncogenesis</i> , 2015, 4, e155-e155.	2.1	24
406	T memory stem cells are the hierarchical apex of adult T-cell leukemia. <i>Blood</i> , 2015, 125, 3527-3535.	0.6	50
407	Circulating microRNAs in Disease Diagnostics and their Potential Biological Relevance. <i>Exs</i> , 2015, , .	1.4	9
408	N-cadherin in cancer dormancy. <i>Cell Death in Therapy</i> , 2015, 1, .	0.3	2
409	The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells. <i>International Journal of Oncology</i> , 2015, 46, 1551-1559.	1.4	39
410	Inhibition of CD147 expression by RNA interference reduces proliferation, invasion and increases chemosensitivity in cancer stem cell-like HT-29 cells. <i>International Journal of Oncology</i> , 2015, 47, 1476-1484.	1.4	9
411	Î2-Arrestin1 promotes the self-renewal of the leukemia-initiating cell-enriched subpopulation in B-lineage acute lymphoblastic leukemia related to DNMT1 activity. <i>Cancer Letters</i> , 2015, 357, 170-178.	3.2	17
412	The rarity of ⁺ ALDH</sup> cells is the key to separation of normal versus leukemia stem cells by ⁺ ALDH</sup> activity in ⁺ AML</sup> patients. <i>International Journal of Cancer</i> , 2015, 137, 525-536.	2.3	46
413	Proteomics reveals the importance of the dynamic redistribution of the subcellular location of proteins in breast cancer cells. <i>Expert Review of Proteomics</i> , 2015, 12, 61-74.	1.3	8
414	Lineage-related cytotoxicity and clonogenic profile of 1,4-benzoquinone-exposed hematopoietic stem and progenitor cells. <i>Toxicology and Applied Pharmacology</i> , 2015, 284, 8-15.	1.3	20
415	Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. <i>Stem Cell Research</i> , 2015, 14, 95-104.	0.3	48
416	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. <i>Nature Medicine</i> , 2015, 21, 178-184.	15.2	459
417	Mitochondria as therapeutic targets for cancer stem cells. <i>World Journal of Stem Cells</i> , 2015, 7, 418.	1.3	48
418	Compensatory angiogenesis and tumor refractoriness. <i>Oncogenesis</i> , 2015, 4, e153-e153.	2.1	88
419	Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways. <i>Stem Cell Reviews and Reports</i> , 2015, 11, 909-918.	5.6	22
420	Thyrospheres From Normal or Malignant Thyroid Tissue Have Different Biological, Functional, and Genetic Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1168-E1178.	1.8	29

#	ARTICLE	IF	CITATIONS
421	Synthesis and antileukemic activities of C10-modified parthenolide analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4737-4745.	1.4	23
422	Ectopic expression of the WWOX gene suppresses stemness of human ovarian cancer stem cells. <i>Oncology Letters</i> , 2015, 9, 1614-1620.	0.8	14
423	Safety and efficacy study of nasopharyngeal cancer stem cell vaccine. <i>Immunology Letters</i> , 2015, 165, 26-31.	1.1	6
424	Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1827-1833.	1.2	23
425	Safety and efficacy study of lung cancer stem cell vaccine. <i>Immunologic Research</i> , 2015, 62, 16-22.	1.3	10
426	SCNVSIm: somatic copy number variation and structure variation simulator. <i>BMC Bioinformatics</i> , 2015, 16, 66.	1.2	32
427	Direct confirmation of quiescence of CD34+CD38- leukemia stem cell populations using single cell culture, their molecular signature and clinicopathological implications. <i>BMC Cancer</i> , 2015, 15, 217.	1.1	14
428	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. <i>Journal of Hematology and Oncology</i> , 2015, 8, 16.	6.9	80
429	Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. <i>Oncogene</i> , 2015, 34, 1843-1852.	2.6	40
430	The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. <i>Leukemia</i> , 2015, 29, 1623-1631.	3.3	34
431	Immune evasion in cancer: Mechanistic basis and therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2015, 35, S185-S198.	4.3	1,122
432	Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. <i>Molecular Cancer</i> , 2015, 14, 179.	7.9	156
433	Targeting tumor metastases: Drug delivery mechanisms and technologies. <i>Journal of Controlled Release</i> , 2015, 219, 215-223.	4.8	32
437	Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. <i>Nature Communications</i> , 2015, 6, 8428.	5.8	53
438	The molecular signature of AML mesenchymal stromal cells reveals candidate genes related to the leukemogenic process. <i>Cancer Letters</i> , 2015, 369, 134-143.	3.2	18
439	Cancer Stem Cell Marker Phenotypes Are Reversible and Functionally Homogeneous in a Preclinical Model of Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 4582-4592.	0.4	22
440	Circulating microRNAs as Hormones: Intercellular and Inter-organ Conveyors of Epigenetic Information?. <i>Exs</i> , 2015, 106, 255-267.	1.4	3
441	Honokiol inhibits melanoma stem cells by targeting notch signaling. <i>Molecular Carcinogenesis</i> , 2015, 54, 1710-1721.	1.3	62

#	ARTICLE	IF	CITATIONS
442	Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype. <i>Leukemia and Lymphoma</i> , 2015, 56, 2408-2415.	0.6	7
443	The molecular mechanisms underlying the therapeutic resistance of cancer stem cells. <i>Archives of Pharmacal Research</i> , 2015, 38, 389-401.	2.7	54
444	Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia. <i>Leukemia</i> , 2015, 29, 988-991.	3.3	24
445	Tenascin-C: A Novel Candidate Marker for Cancer Stem Cells in Glioblastoma Identified by Tissue Microarrays. <i>Journal of Proteome Research</i> , 2015, 14, 814-822.	1.8	39
447	p53 orchestrates between normal differentiation and cancer. <i>Seminars in Cancer Biology</i> , 2015, 32, 10-17.	4.3	53
448	Nitric oxide induces cancer stem cell-like phenotypes in human lung cancer cells. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 308, C89-C100.	2.1	47
449	HIF1 α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells. <i>Molecular Cancer Research</i> , 2015, 13, 556-564.	1.5	77
450	Cancer stem cells: perspectives for therapeutic targeting. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 91-97.	2.0	63
451	Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2016, 07, .	0.3	28
452	Chromatin Dynamics and Epigenetics of Stem Cells and Stem-Like Cancer Cells. , 2016, , 311-327.		0
453	Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. <i>Journal of Cancer</i> , 2016, 7, 1497-1514.	1.2	71
454	Stem Cells and Cancer. <i>Journal of Cell Science & Therapy</i> , 2016, 07, .	0.3	0
455	Cancer stem cells: lessons learned from the leukemic stem cells. <i>Turkish Journal of Biology</i> , 2016, 40, 1012-1017.	2.1	0
456	Therapeutic Effectiveness of Anticancer Phytochemicals on Cancer Stem Cells. <i>Toxins</i> , 2016, 8, 199.	1.5	48
457	Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS. <i>Frontiers in Oncology</i> , 2016, 6, 206.	1.3	4
458	Effect of Melatonin in Epithelial Mesenchymal Transition Markers and Invasive Properties of Breast Cancer Stem Cells of Canine and Human Cell Lines. <i>PLoS ONE</i> , 2016, 11, e0150407.	1.1	67
459	Dissecting the Origin of Breast Cancer Subtype Stem Cell and the Potential Mechanism of Malignant Transformation. <i>PLoS ONE</i> , 2016, 11, e0165001.	1.1	11
460	Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy. <i>Frontiers in Pharmacology</i> , 2016, 7, 477.	1.6	93

#	ARTICLE	IF	CITATIONS
461	Microenvironmental cues for Tâ€cell acute lymphoblastic leukemia development. Immunological Reviews, 2016, 271, 156-172.	2.8	32
462	Molecular landscapes of human hematopoietic stem cells in health and leukemia. Annals of the New York Academy of Sciences, 2016, 1370, 5-14.	1.8	24
463	Burning Fat Fuels Leukemic Stem Cell Heterogeneity. Cell Stem Cell, 2016, 19, 1-2.	5.2	34
464	Systems Pharmacology and Pharmacodynamics. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , .	0.2	9
465	Let-7g-5p inhibits epithelial-mesenchymal transition consistent with reduction of glioma stem cell phenotypes by targeting VSIG4 in glioblastoma. Oncology Reports, 2016, 36, 2967-2975.	1.2	29
466	Cancer Stem Cell Hypothesis for Therapeutic Innovation in Clinical Oncology? Taking the Root Out, Not Chopping the Leaf. OMICS A Journal of Integrative Biology, 2016, 20, 681-691.	1.0	47
467	Using Systems Pharmacology to Advance Oncology Drug Development. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 421-463.	0.2	1
468	The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica, 2016, 101, 1451-1459.	1.7	55
469	A physical mechanism of cancer heterogeneity. Scientific Reports, 2016, 6, 20679.	1.6	25
470	Stem cells and cancer: A review. Asian Pacific Journal of Tropical Disease, 2016, 6, 406-420.	0.5	1
471	Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population. Lung, 2016, 194, 393-400.	1.4	9
472	NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancerâ€Initiating Cells. Cancer Research, 2016, 76, 3411-3421.	0.4	49
474	Feedback mechanisms control coexistence in a stem cell model of acute myeloid leukaemia. Journal of Theoretical Biology, 2016, 401, 43-53.	0.8	23
475	15â€Methyleneâ€Eburnamonine Kills Leukemic Stem Cells and Reduces Engraftment in a Humanized Bone Marrow Xenograft Mouse Model of Leukemia. ChemMedChem, 2016, 11, 2392-2397.	1.6	3
477	Clinical significance of Gremlin 1 in cervical cancer and its effects on cancer stem cell maintenance. Oncology Reports, 2016, 35, 391-397.	1.2	23
478	Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. Journal of Biological Chemistry, 2016, 291, 21984-22000.	1.6	30
479	Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Personalized Medicine, 2016, 13, 469-484.	0.8	8
480	Pluripotent Stem Cells From Livestock. , 2016, , 312-354.		0

#	ARTICLE	IF	CITATIONS
481	Metabolism in Cancer. Recent Results in Cancer Research, 2016, , .	1.8	5
482	Metabolic Features of Cancer Treatment Resistance. Recent Results in Cancer Research, 2016, 207, 135-156.	1.8	34
484	Apoptotic Caspases in Promoting Cancer: Implications from Their Roles in Development and Tissue Homeostasis. Advances in Experimental Medicine and Biology, 2016, 930, 89-112.	0.8	27
485	Critical Updates to the Leukemia Stem Cell Model. , 2016, , 101-119.		2
486	Current Concepts of How to Eliminate Cancer Stem Cells. , 2016, , 181-212.		0
487	Tumor Heterogeneity Assessed by 18F-FDG PET/CT Is Not Significantly Associated with Nodal Metastasis in Breast Cancer Patients. Oncology Research and Treatment, 2016, 39, 61-66.	0.8	9
488	Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia. European Journal of Haematology, 2016, 97, 239-244.	1.1	9
490	Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia. Journal of Hematology and Oncology, 2016, 9, 36.	6.9	21
491	Reprogramming strategies for the establishment of novel human cancer models. Cell Cycle, 2016, 15, 2393-2397.	1.3	3
492	Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy. Cell Death and Disease, 2016, 7, e2246-e2246.	2.7	40
493	Regulation of Stem Cell Self-Renewal and Oncogenesis by RNA-Binding Proteins. Advances in Experimental Medicine and Biology, 2016, 907, 153-188.	0.8	19
494	NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?. Journal of Nanobiotechnology, 2016, 14, 17.	4.2	35
495	A mathematical model of tumor growth and its response to single irradiation. Theoretical Biology and Medical Modelling, 2016, 13, 6.	2.1	65
496	Radiation Sensitivity of Human CD34 ⁺ Cells Versus Peripheral Blood T Lymphocytes of Newborns and Adults: DNA Repair and Mutagenic Effects. Radiation Research, 2016, 185, 580-590.	0.7	21
497	CD45 ^{RA} , a specific marker for leukaemia stem cell subpopulations in acute myeloid leukaemia. British Journal of Haematology, 2016, 173, 219-235.	1.2	47
498	Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells. International Journal of Oncology, 2016, 48, 829-835.	1.4	17
499	Total syntheses and structure-activity relationship study of parthenolide analogues. Tetrahedron Letters, 2016, 57, 874-877.	0.7	23
500	Somatic mosaicism: on the road to cancer. Nature Reviews Cancer, 2016, 16, 43-55.	12.8	113

#	ARTICLE	IF	CITATIONS
501	Cell cycle related genes up-regulated in human colorectal development predict the overall survival of late-stage colorectal cancer patients. <i>Molecular BioSystems</i> , 2016, 12, 541-552.	2.9	7
502	Numerical resolution of a model of tumour growth. <i>Mathematical Medicine and Biology</i> , 2016, 33, 57-85.	0.8	2
503	Intratumor Heterogeneity in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 169-189.	0.8	111
504	p75 neurotrophin receptor expression is a characteristic of the mitotically quiescent cancer stem cell population present in esophageal squamous cell carcinoma. <i>International Journal of Oncology</i> , 2016, 48, 1943-1954.	1.4	25
505	Cancer stem cells: a metastasizing menace!. <i>Cancer Medicine</i> , 2016, 5, 649-655.	1.3	29
508	Detection of circulating tumor cells by p75NTR expression in patients with esophageal cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 40.	0.8	13
509	Leukaemia 'firsts' in cancer research and treatment. <i>Nature Reviews Cancer</i> , 2016, 16, 163-172.	12.8	67
510	Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients. <i>Cancer Research</i> , 2016, 76, 2082-2086.	0.4	24
511	Mathematical modeling of bone marrow peripheral blood dynamics in the disease state based on current emerging paradigms, part I. <i>Mathematical Biosciences</i> , 2016, 274, 83-93.	0.9	3
512	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. <i>Clinical Cancer Research</i> , 2016, 22, 2051-2061.	3.2	52
513	Emerging importance of dietary phytochemicals in fight against cancer: Role in targeting cancer stem cells. <i>Critical Reviews in Food Science and Nutrition</i> , 2017, 57, 3449-3463.	5.4	61
514	Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells. <i>Molecular Cancer</i> , 2017, 16, 28.	7.9	106
515	A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens. <i>Blood Cancer Journal</i> , 2017, 7, e529-e529.	2.8	11
516	Tumor-Initiating Cells: a critical review of isolation approaches and new challenges in targeting strategies. <i>Molecular Cancer</i> , 2017, 16, 40.	7.9	64
517	The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia. <i>Clinical and Translational Oncology</i> , 2017, 19, 1059-1066.	1.2	10
518	Somatic clonal evolution: A selection-centric perspective. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 139-150.	3.3	61
519	Neoplasms in the bone marrow niches: disturbance of the microecosystem. <i>International Journal of Hematology</i> , 2017, 105, 558-565.	0.7	1
520	A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties. <i>Experimental Cell Research</i> , 2017, 352, 218-224.	1.2	8

#	ARTICLE	IF	CITATIONS
521	Alteration Analysis of Bone Marrow Mesenchymal Stromal Cells from De Novo Acute Myeloid Leukemia Patients at Diagnosis. <i>Stem Cells and Development</i> , 2017, 26, 709-722.	1.1	39
523	Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications. <i>Experimental Hematology</i> , 2017, 51, 17-24.	0.2	31
524	p53 and its mutants on the slippery road from stemness to carcinogenesis. <i>Carcinogenesis</i> , 2017, 38, 347-358.	1.3	28
525	Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. <i>Drugs</i> , 2017, 77, 1091-1103.	4.9	116
526	Characterization of cancer stem cell drug resistance in the human colorectal cancer cell lines HCT116 and SW480. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 29-35.	1.0	28
527	Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. <i>EMBO Molecular Medicine</i> , 2017, 9, 918-932.	3.3	36
528	CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission. <i>Blood Cancer Journal</i> , 2017, 7, e567-e567.	2.8	38
529	Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 183-198.	3.3	32
530	PMP22 Regulates Self-Renewal and Chemoresistance of Gastric Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1187-1198.	1.9	37
531	Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers. <i>EMBO Molecular Medicine</i> , 2017, 9, 655-671.	3.3	33
532	Cancer stem cell molecular markers verified in vivo. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2017, 11, 43-54.	0.2	14
533	Intratumor and Intertumor Heterogeneity in Melanoma. <i>Translational Oncology</i> , 2017, 10, 956-975.	1.7	217
534	Influence of salinomycin treatment on division and movement of individual cancer cells cultured in normoxia or hypoxia evaluated with time-lapse digital holographic microscopy. <i>Cell Cycle</i> , 2017, 16, 2128-2138.	1.3	22
535	Clonal evolution in leukemia. <i>Nature Medicine</i> , 2017, 23, 1135-1145.	15.2	93
536	Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells. <i>Scientific Reports</i> , 2017, 7, 12317.	1.6	30
537	Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance. <i>Oncology Letters</i> , 2017, 14, 5811-5818.	0.8	10
538	Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. <i>Cancer Biomarkers</i> , 2017, 21, 41-53.	0.8	3
539	Osteopontin plays a unique role in resistance of CD34 +/CD123 + human leukemia cell lines KG1a to parthenolide. <i>Life Sciences</i> , 2017, 189, 89-95.	2.0	11

#	ARTICLE	IF	CITATIONS
540	CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients. <i>Blood Cancer Journal</i> , 2017, 7, e601-e601.	2.8	10
541	Expression of embryonic stem cell markers in acute myeloid leukemia. <i>Tumor Biology</i> , 2017, 39, 101042831771662.	0.8	21
542	Endometrial cytopathology. An image analysis approach using the Ki-67 biomarker. <i>Cytopathology</i> , 2017, 28, 385-390.	0.4	2
543	The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation. <i>Blood</i> , 2017, 130, 1336-1346.	0.6	39
544	The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis. <i>Future Oncology</i> , 2017, 13, 2555-2570.	1.1	7
545	Infectious Agents in Childhood Leukemia. <i>Archives of Medical Research</i> , 2017, 48, 305-313.	1.5	4
546	Relevance of Stem Cells. , 2017, , 883-888.		0
547	Overview of Cancer Stem Cells and Stemness for Community Oncologists. <i>Targeted Oncology</i> , 2017, 12, 387-399.	1.7	103
548	RBP4-STRA6 Pathway Drives Cancer Stem Cell Maintenance and Mediates High-Fat Diet-Induced Colon Carcinogenesis. <i>Stem Cell Reports</i> , 2017, 9, 438-450.	2.3	78
549	Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. <i>Molecular Therapy</i> , 2017, 25, 2202-2213.	3.7	109
550	Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. <i>Stem Cells Translational Medicine</i> , 2017, 6, 840-850.	1.6	5
551	AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells. <i>Clinical Cancer Research</i> , 2017, 23, 2781-2794.	3.2	104
552	Correlation between mucin biology and tumor heterogeneity in lung cancer. <i>Seminars in Cell and Developmental Biology</i> , 2017, 64, 73-78.	2.3	26
554	Curcumin: An age-old anti-inflammatory and anti-neoplastic agent. <i>Journal of Traditional and Complementary Medicine</i> , 2017, 7, 339-346.	1.5	228
555	Selenium and Cancer Stem Cells. <i>Advances in Cancer Research</i> , 2017, 136, 235-257.	1.9	21
556	Current Progresses of Single Cell DNA Sequencing in Breast Cancer Research. <i>International Journal of Biological Sciences</i> , 2017, 13, 949-960.	2.6	15
557	The Cancer Stem Cell Niche. , 2017, , 167-184.		2
558	Cancer cell-soluble factors reprogram mesenchymal stromal cells to slow cycling, chemoresistant cells with a more stem-like state. <i>Stem Cell Research and Therapy</i> , 2017, 8, 254.	2.4	36

#	ARTICLE	IF	CITATIONS
559	CD133 and MYCN Amplification Induce Chemo-Resistance and Reduce Average Survival Time in Pediatric Neuroblastoma. <i>Journal of Stem Cell Research & Therapy</i> , 2017, 07, .	0.3	0
560	Regeneration of cervical reserve cell-like cells from human induced pluripotent stem cells (iPSCs): A new approach to finding targets for cervical cancer stem cell treatment. <i>Oncotarget</i> , 2017, 8, 40935-40945.	0.8	12
561	Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 812-824.	1.8	12
562	Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts. <i>Oncotarget</i> , 2017, 8, 32101-32116.	0.8	32
563	The interplay of leukemia cells and the bone marrow microenvironment. <i>Blood</i> , 2018, 131, 1507-1511.	0.6	87
564	CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting. <i>Haematologica</i> , 2018, 103, 447-455.	1.7	39
565	Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 420-424.	1.0	7
566	CD133 expression and <i>MYCN</i> amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma. <i>Journal of International Medical Research</i> , 2018, 46, 1209-1220.	0.4	13
567	A Synthetic Binder of Breast Cancer Stem Cells. <i>Chemistry - A European Journal</i> , 2018, 24, 3694-3698.	1.7	3
568	A greater birthweight increases the risk of acute leukemias in Mexican children—experience from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia (<sc>MIGICCL</sc>). <i>Cancer Medicine</i> , 2018, 7, 1528-1536.	1.3	13
569	EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. <i>Oncogene</i> , 2018, 37, 4073-4093.	2.6	30
570	Inhibition of DNMT suppresses the stemness of colorectal cancer cells through down-regulating Wnt signaling pathway. <i>Cellular Signalling</i> , 2018, 47, 79-87.	1.7	30
571	Antipsychotic dopamine receptor antagonists, cancer, and cancer stem cells. <i>Archives of Pharmacal Research</i> , 2018, 41, 384-408.	2.7	39
572	The role of Aurora-A in cancer stem cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 98, 89-92.	1.2	23
573	Using Carboxy Fluorescein Succinimidyl Ester (CFSE) to Identify Quiescent Glioblastoma Stem-Like Cells. <i>Methods in Molecular Biology</i> , 2018, 1686, 59-67.	0.4	4
574	Single cell analysis of normal and leukemic hematopoiesis. <i>Molecular Aspects of Medicine</i> , 2018, 59, 85-94.	2.7	53
575	Functionalised nanomaterials for eradication of CSCs, a promising approach for overcoming tumour heterogeneity. <i>Journal of Drug Targeting</i> , 2018, 26, 649-657.	2.1	9
576	Clinical Application of Stem Cell Biology in Esophageal Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 49-62.	0.1	0

#	ARTICLE	IF	CITATIONS
578	T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. <i>Blood Reviews</i> , 2018, 32, 36-51.	2.8	120
579	Ultimate Precision: Targeting Cancer but Not Normal Self-replication. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 950-963.	1.8	13
580	The kinetics of 18F-FDG in lung cancer: compartmental models and voxel analysis. <i>EJNMMI Research</i> , 2018, 8, 88.	1.1	3
581	CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 507, 426-432.	1.0	24
582	Cancer Connectors: Connexins, Gap Junctions, and Communication. <i>Frontiers in Oncology</i> , 2018, 8, 646.	1.3	61
583	Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias. <i>Nature Communications</i> , 2018, 9, 5280.	5.8	46
584	The role of cancer stem cells in the modulation of anti-tumor immune responses. <i>Seminars in Cancer Biology</i> , 2018, 53, 189-200.	4.3	80
585	Nanomedicine in cancer stem cell therapy: from fringe to forefront. <i>Cell and Tissue Research</i> , 2018, 374, 427-438.	1.5	28
586	<i>SUSD2</i>, a putative tumor suppressor gene, inhibits growth of colorectal cancer cells. <i>Annals of Cancer Research and Therapy</i> , 2018, 26, 77-81.	0.1	0
587	Integrated Stress Response Activity Marks Stem Cells in Normal Hematopoiesis and Leukemia. <i>Cell Reports</i> , 2018, 25, 1109-1117.e5.	2.9	88
588	<sc>AMPK</sc> promotes the survival of colorectal cancer stem cells. <i>Animal Models and Experimental Medicine</i> , 2018, 1, 134-142.	1.3	19
589	c-MPL Is a Candidate Surface Marker and Confers Self-Renewal, Quiescence, Chemotherapy Resistance, and Leukemia Initiation Potential in Leukemia Stem Cells. <i>Stem Cells</i> , 2018, 36, 1685-1696.	1.4	15
590	Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy. <i>Seminars in Cancer Biology</i> , 2018, 53, 75-89.	4.3	90
591	Rapid phenotyping of cancer stem cells using multichannel nanosensor arrays. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1931-1939.	1.7	22
592	let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer. <i>Scientific Reports</i> , 2018, 8, 7840.	1.6	45
593	E-cadherin regulates proliferation of colorectal cancer stem cells through NANOG. <i>Oncology Reports</i> , 2018, 40, 693-703.	1.2	19
594	Stem Cells and Cancer. , 2018, , 271-309.		0
595	Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. <i>Oncolmmunology</i> , 2018, 7, e1472195.	2.1	21

#	ARTICLE	IF	CITATIONS
596	Cell Polarity and Division Symmetry Analyses in Transformed Blood Cells. <i>Methods in Molecular Biology</i> , 2018, 1821, 257-266.	0.4	0
598	Coming of Age: CD96 Emerges as Modulator of Immune Responses. <i>Frontiers in Immunology</i> , 2018, 9, 1072.	2.2	88
599	Resveratrol Chemosensitizes TNF- α -Induced Survival of 5-FU-Treated Colorectal Cancer Cells. <i>Nutrients</i> , 2018, 10, 888.	1.7	85
600	Lgr5 in cancer biology: functional identification of Lgr5 in cancer progression and potential opportunities for novel therapy. <i>Stem Cell Research and Therapy</i> , 2019, 10, 219.	2.4	52
601	Induced pluripotent stem cells as a novel cancer vaccine. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1191-1197.	1.4	10
602	Cell population heterogeneity driven by stochastic partition and growth optimality. <i>Scientific Reports</i> , 2019, 9, 9406.	1.6	12
603	The connection between the Th17 cell related cytokines and cancer stem cells in cancer: Novel therapeutic targets. <i>Immunology Letters</i> , 2019, 213, 9-20.	1.1	16
604	The Many Facets of Tumor Heterogeneity: Is Metabolism Lagging Behind?. <i>Cancers</i> , 2019, 11, 1574.	1.7	28
605	Functional profiling of single CRISPR/Cas9-edited human long-term hematopoietic stem cells. <i>Nature Communications</i> , 2019, 10, 4730.	5.8	30
606	In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells. <i>British Journal of Cancer</i> , 2019, 121, 846-856.	2.9	13
607	Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept. <i>Cells</i> , 2019, 8, 1330.	1.8	18
608	The invasion of de-differentiating cancer cells into hierarchical tissues. <i>PLoS Computational Biology</i> , 2019, 15, e1007167.	1.5	16
609	VEGF/Neuropilin Signaling in Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 490.	1.8	76
610	Primitive Cancer Cell States: A Target for Drug Screening?. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 161-171.	4.0	10
611	Stem Cells Heterogeneity in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	2
612	Energy metabolism and drug response in myeloid leukaemic stem cells. <i>British Journal of Haematology</i> , 2019, 186, 524-537.	1.2	12
613	Cancer Stem Cells: The Players of Immune Evasion from Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 223-249.	0.1	6
614	Cancer Stem Cells: From Birth to Death. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 1-30.	0.1	1

#	ARTICLE	IF	CITATIONS
615	Heterogeneity of Small Cell Lung Cancer Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 41-57.	0.8	19
616	Heterogeneity of Hepatic Cancer Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 59-81.	0.8	34
617	Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells. <i>Blood Advances</i> , 2019, 3, 419-431.	2.5	11
619	A Role for Lipid Mediators in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2425.	1.8	17
620	YTHDF1 Regulates Tumorigenicity and Cancer Stem Cell-Like Activity in Human Colorectal Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 332.	1.3	223
621	Therapeutic targeting of gastrointestinal cancer stem cells. <i>Regenerative Medicine</i> , 2019, 14, 331-343.	0.8	9
622	Preclinical animal tumor models to study prevention of colon cancer recurrence by curcumin. , 2019, , 293-307.		2
623	A nonlinear mathematical model of cell-mediated immune response for tumor phenotypic heterogeneity. <i>Journal of Theoretical Biology</i> , 2019, 471, 42-50.	0.8	16
624	Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. <i>Leukemia</i> , 2019, 33, 2169-2182.	3.3	52
625	CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/ β 2-catenin signaling pathway. <i>Pediatric Research</i> , 2019, 85, 1024-1031.	1.1	15
626	Tenascin-C is involved in promotion of cancer stemness via the Akt/HIF1 α axis in esophageal squamous cell carcinoma. <i>Experimental and Molecular Pathology</i> , 2019, 109, 104239.	0.9	13
627	Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2019, 17, 102.	1.8	18
628	<sc>PTPRK</sc> suppresses progression and chemoâ€resistance of colon cancer cells via direct inhibition of proâ€oncogenic <sc>CD</sc>133. <i>FEBS Open Bio</i> , 2019, 9, 935-946.	1.0	9
629	Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients. <i>BMC Cancer</i> , 2019, 19, 155.	1.1	7
630	Cancer stem cell theory. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 814-818.	0.6	15
631	The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy. <i>Cancer Microenvironment</i> , 2019, 12, 133-148.	3.1	36
632	Tumor heterogeneity of acute myeloid leukemia: insights from single-cell sequencing. <i>Blood Science</i> , 2019, 1, 73-76.	0.4	5
633	Small RNA sequencing revealed aberrant piRNA expression profiles in colorectal cancer. <i>Oncology Reports</i> , 2019, 42, 263-272.	1.2	24

#	ARTICLE	IF	CITATIONS
634	Cancer Stem Cells. , 2019, , 77-87.		8
635	Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. Leukemia Research, 2019, 77, 42-50.	0.4	16
636	Current evidence and future perspectives for curcumin and its analogues as promising adjuncts to oxaliplatin: state-of-the-art. Pharmacological Research, 2019, 141, 343-356.	3.1	29
637	Mathematical modeling of bone marrow " peripheral blood dynamics in the disease state based on current emerging paradigms, part II. Journal of Theoretical Biology, 2019, 460, 37-55.	0.8	4
638	A rare subgroup of leukemia stem cells harbors relapse-inducing potential in acute lymphoblastic leukemia. Experimental Hematology, 2019, 69, 1-10.	0.2	11
639	Metabolism and epigenetics of pancreatic cancer stem cells. Seminars in Cancer Biology, 2019, 57, 19-26.	4.3	45
640	Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165339.	1.8	79
641	Cancer cells stemness: A doorstep to targeted therapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165424.	1.8	96
642	The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia. Haematologica, 2020, 105, 687-696.	1.7	14
643	Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β2-catenin-driven hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 104-118.	1.8	88
644	Tumor-Based Genetic Testing and Familial Cancer Risk. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036590.	2.9	27
645	DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer. Carcinogenesis, 2020, 41, 303-312.	1.3	20
646	Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. Haematologica, 2020, 105, 721-729.	1.7	21
647	Role and molecular mechanism of stem cells in colorectal cancer initiation. Journal of Drug Targeting, 2020, 28, 1-10.	2.1	13
648	The Clinical Impact of Cancer Stem Cells. Oncologist, 2020, 25, 123-131.	1.9	66
649	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nature Reviews Cancer, 2020, 20, 158-173.	12.8	181
650	Are Leukaemic Stem Cells Restricted to a Single Cell Lineage?. International Journal of Molecular Sciences, 2020, 21, 45.	1.8	1
651	Papillary Thyroid Cancer Tumor Spheres Cultured by Passaging Without Sorting Exhibit Cancer Stemness. Anticancer Research, 2020, 40, 3801-3809.	0.5	2

#	ARTICLE	IF	CITATIONS
652	Breast Cancer Heterogeneity and Response to Novel Therapeutics. <i>Cancers</i> , 2020, 12, 3271.	1.7	40
653	The Role of Bone Stem Cell Niches in Bone Metastasis. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 7713.	1.3	0
654	Addressing Cellular Heterogeneity in Cancer through Precision Proteomics. <i>Journal of Proteome Research</i> , 2020, 19, 3607-3619.	1.8	8
655	Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5278.	1.8	20
656	Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5084.	1.8	15
657	Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5626.	1.8	20
658	Therapeutic Effects of Curcumin Against Colorectal Cancer. , 2020, , 209-222.		0
660	Stem cells in cancer initiation and progression. <i>Journal of Cell Biology</i> , 2020, 219, .	2.3	69
661	Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression. <i>Cells</i> , 2020, 9, 1879.	1.8	53
662	Differentiation of Cancer Stem Cells through Nanoparticle Surface Engineering. <i>ACS Nano</i> , 2020, 14, 15276-15285.	7.3	33
663	Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses. <i>Neoplasia</i> , 2020, 22, 663-678.	2.3	37
664	CD34+CD38 ⁺ CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. <i>Cancers</i> , 2020, 12, 1174.	1.7	7
665	Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells. <i>Cell Reports</i> , 2020, 31, 107688.	2.9	31
666	Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells. <i>Blood</i> , 2020, 136, 1507-1519.	0.6	57
667	Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model. <i>Leukemia</i> , 2020, 34, 3242-3255.	3.3	4
668	Hybrid Epithelial/Mesenchymal State in Cancer Metastasis: Clinical Significance and Regulatory Mechanisms. <i>Cells</i> , 2020, 9, 623.	1.8	76
669	Role of colorectal cancer stem cells in resistance to apoptosis and treatment in colorectal cancer. , 2020, , 57-74.		0
670	Exploiting Cancer TM s Tactics to Make Cancer a Manageable Chronic Disease. <i>Cancers</i> , 2020, 12, 1649.	1.7	3

#	ARTICLE	IF	CITATIONS
671	<p>Self-Renewal Signalling Pathway Inhibitors: Perspectives on Therapeutic Approaches for Cancer Stem Cells</p>. OncoTargets and Therapy, 2020, Volume 13, 525-540.	1.0	21
672	Anti-proliferative and Anti-metastatic Potential of High Molecular Weight Secretory Molecules from Probiotic Lactobacillus Reuteri Cell-Free Supernatant Against Human Colon Cancer Stem-Like Cells (HT29-ShE). International Journal of Peptide Research and Therapeutics, 2020, 26, 2619-2631.	0.9	22
673	Vitamin D and Haematopoiesis. Current Tissue Microenvironment Reports, 2020, 1, 1-11.	1.3	0
674	The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia. Frontiers in Oncology, 2020, 10, 393.	1.3	14
675	Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact. PLoS ONE, 2020, 15, e0229593.	1.1	3
676	Overcoming Wntâ€²-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nature Cell Biology, 2020, 22, 689-700.	4.6	89
677	Lineage Decision-Making within Normal Haematopoietic and Leukemic Stem Cells. International Journal of Molecular Sciences, 2020, 21, 2247.	1.8	2
678	A general view of CD33⁺ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblastic leukemia therapy. Blood Research, 2020, 55, 10-16.	0.5	21
679	Disulfiram/cytarabine eradicates a subset of acute myeloid leukemia stem cells with high aldehyde dehydrogenase expression. Leukemia Research, 2020, 92, 106351.	0.4	13
680	Engineering in Medicine To Address the Challenge of Cancer Drug Resistance: From Micro- and Nanotechnologies to Computational and Mathematical Modeling. Chemical Reviews, 2021, 121, 3352-3389.	23.0	41
681	Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy. British Journal of Haematology, 2021, 192, 137-145.	1.2	6
682	Ultra-high-dose-rate FLASH and Conventional-Dose-Rate Irradiation Differentially Affect Human Acute Lymphoblastic Leukemia and Normal Hematopoiesis. International Journal of Radiation Oncology Biology Physics, 2021, 109, 819-829.	0.4	66
683	A cell competitionâ€“based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. Journal of Biological Chemistry, 2021, 296, 100179.	1.6	6
684	Gut microbiota profiling in hematopoietic stem cell transplant recipients: Towards personalized medicine. Medical Journal Armed Forces India, 2021, 77, 22-27.	0.3	2
685	Autophagy and senescence: Insights from normal and cancer stem cells. Advances in Cancer Research, 2021, 150, 147-208.	1.9	5
686	Targeting leukemia stem cells in T-cell acute lymphoblastic leukemia (T-ALL). , 2021, , 161-197.		0
687	Theranostics for Breast Cancer Stem Cells. Advances in Experimental Medicine and Biology, 2021, 1187, 267-281.	0.8	2
688	Studying leukemia stem cell properties and vulnerabilities with human iPSCs. Stem Cell Research, 2021, 50, 102117.	0.3	3

#	ARTICLE	IF	CITATIONS
689	Stem Cells an Overview. , 2021, , 1-21.		1
690	Bozepinib: A Promising Selective Derivative Targeting Breast Cancer Stem Cells. , 0, , .		0
691	Biophysical informatics approach for quantifying phenotypic heterogeneity in cancer cell migration in confined microenvironments. <i>Bioinformatics</i> , 2021, , .	1.8	9
692	Exosome-mediated transfer of CD44 from high-metastatic ovarian cancer cells promotes migration and invasion of low-metastatic ovarian cancer cells. <i>Journal of Ovarian Research</i> , 2021, 14, 38.	1.3	32
693	DDX3X: structure, physiologic functions and cancer. <i>Molecular Cancer</i> , 2021, 20, 38.	7.9	95
694	An emerging role for cellular crosstalk in the cancer stem cell niche. <i>Journal of Pathology</i> , 2021, 254, 384-394.	2.1	31
695	MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2021, 21, 132-152.	0.8	14
696	Self-Renewal Pathways in Acute Myeloid Leukemia Stem Cells. , 0, , .		0
698	Homoharringtonine inhibits melanoma cells proliferation in vitro and vivo by inducing DNA damage, apoptosis, and G2/M cell cycle arrest. <i>Archives of Biochemistry and Biophysics</i> , 2021, 700, 108774.	1.4	14
699	Models of Functional Heterogeneity and Targeting Strategies for Cancer Stem Cells. , 2021, 5, 1-9.		0
700	The RAR β Oncogene: An Achilles Heel for Some Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3632.	1.8	12
701	Anti-oncogenic activities exhibited by paracrine factors of MSCs can be mediated by modulation of KITLG and DKK1 genes in glioma SCs in vitro. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 147-165.	2.0	10
702	Disruption of the MSL complex inhibits tumour maintenance by exacerbating chromosomal instability. <i>Nature Cell Biology</i> , 2021, 23, 401-412.	4.6	13
703	Human CD34-negative hematopoietic stem cells: The current understanding of their biological nature. <i>Experimental Hematology</i> , 2021, 96, 13-26.	0.2	13
704	The Role of Serotonin in Breast Cancer Stem Cells. <i>Molecules</i> , 2021, 26, 3171.	1.7	9
705	Understanding Normal and Pathological Hematopoietic Stem Cell Biology Using Mathematical Modelling. <i>Current Stem Cell Reports</i> , 2021, 7, 109-120.	0.7	6
706	Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics. <i>Leukemia</i> , 2022, 36, 58-67.	3.3	9
707	Cancer Stem Cells in Tumor Modeling: Challenges and Future Directions. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2100017.	1.7	13

#	ARTICLE	IF	CITATIONS
708	Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor β and the EGFR/HER2 signaling pathway. <i>Biochemical Pharmacology</i> , 2021, 190, 114635.	2.0	7
709	Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2021, 165, 316-321.	0.2	3
710	Oncogenes, Proto-Oncogenes, and Lineage Restriction of Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9667.	1.8	12
711	Tumor-initiating stem cell shapes its microenvironment into an immunosuppressive barrier and pro-tumorigenic niche. <i>Cell Reports</i> , 2021, 36, 109674.	2.9	33
712	Prognostic Impact of Flow Cytometric Measurement of G Proteinâ€‘Coupled Receptor 56 (GPR56) in Acute Myeloid Leukemia. <i>The Egyptian Journal of Hospital Medicine</i> , 2021, 85, 2788-2793.	0.0	0
713	Cancer Stem Cell Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1311, 161-172.	0.8	3
715	Breast Cancer Stem Cells: Role in Tumor Initiation, Progression, and Targeted Therapy. <i>Molecular Pathology Library</i> , 2015, , 63-77.	0.1	1
716	Isolation of Melanoma Cell Subpopulations Using Negative Selection. <i>Methods in Molecular Biology</i> , 2014, 1102, 501-512.	0.4	5
717	Early Hematopoietic Differentiation in Acute Lymphoblastic Leukemia: The Interplay Between Leukemia-Initiating Cells and Abnormal Bone Marrow Microenvironment. , 2016, , 291-318.		2
719	Mitochondrial Metabolism in Cancer. A Tangled Topic. Which Role for Proteomics?. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1158, 1-16.	0.8	3
720	Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 52.	2.8	55
721	Identification of a subpopulation of long-term tumor-initiating cells in colon cancer. <i>Bioscience Reports</i> , 2020, 40, .	1.1	7
723	Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance. <i>Cancer Research</i> , 2019, 79, 5799-5811.	0.4	24
724	TCR-dependent transformation of mature memory phenotype T cells in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 3834-3845.	3.9	62
725	Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38â€‘ Leukemia Stem Cells Derived from KG1â€‘ Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway. <i>Medical Science Monitor</i> , 2020, 26, e918207.	0.5	17
726	A Bmi1-miRNAs Cross-Talk Modulates Chemotherapy Response to 5-Fluorouracil in Breast Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e73268.	1.1	41
727	Tumor-Specific Chromosome Mis-Segregation Controls Cancer Plasticity by Maintaining Tumor Heterogeneity. <i>PLoS ONE</i> , 2013, 8, e80898.	1.1	16
728	Cell Fate Decisions in Malignant Hematopoiesis: Leukemia Phenotype Is Determined by Distinct Functional Domains of the MN1 Oncogene. <i>PLoS ONE</i> , 2014, 9, e112671.	1.1	15

#	ARTICLE	IF	CITATIONS
729	Maintenance of Leukemia-Initiating Cells Is Regulated by the CDK Inhibitor Inca1. PLoS ONE, 2014, 9, e115578.	1.1	3
730	Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations. PLoS ONE, 2015, 10, e0135760.	1.1	15
731	Stem cell and cancer stem cell games on the ECM field. Journal of Cancer Stem Cell Research, 2013, 1, 1.	1.1	5
732	Mesenchymal Stem Cell-Breast Cancer Stem Cell: Relevance to Dormancy. Journal of Cancer Stem Cell Research, 2016, 4, 1.	1.1	3
733	Hitting the bull's eye: targeting HMGA1 in cancer stem cells. Expert Review of Anticancer Therapy, 0, 1-8.	1.1	2
735	CD44variant exon 9 plays an important role in colon cancer initiating cells. Oncotarget, 2013, 4, 785-791.	0.8	30
736	Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer. Oncotarget, 2016, 7, 53137-53152.	0.8	22
737	Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. Oncotarget, 2016, 7, 72685-72698.	0.8	21
738	Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer. Oncotarget, 2016, 7, 76920-76933.	0.8	34
739	The deubiquitinase <i>USP54</i> is overexpressed in colorectal cancer stem cells and promotes intestinal tumorigenesis. Oncotarget, 2016, 7, 74427-74434.	0.8	34
740	Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion. Oncotarget, 2016, 7, 78095-78109.	0.8	29
741	Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget, 2017, 8, 6914-6928.	0.8	38
742	Oncogenic mechanisms of Lin28 in breast cancer: new functions and therapeutic opportunities. Oncotarget, 2017, 8, 25721-25735.	0.8	27
743	SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress. Oncotarget, 2017, 8, 16712-16727.	0.8	18
744	Involvement of Polo-like kinase 1 (Plk1) in quiescence regulation of cancer stem-like cells of the gastric cancer cell lines. Oncotarget, 2017, 8, 37633-37645.	0.8	11
745	FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin. Oncotarget, 2018, 9, 25148-25165.	0.8	39
746	The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget, 2011, 2, 313-320.	0.8	23
747	Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget, 2015, 6, 651-661.	0.8	159

#	ARTICLE	IF	CITATIONS
748	Phenotypic Screening Reveals Topoisomerase I as a Breast Cancer Stem Cell Therapeutic Target. <i>Oncotarget</i> , 2012, 3, 998-1010.	0.8	14
749	A network-based method for identifying prognostic gene modules in lung squamous carcinoma. <i>Oncotarget</i> , 2016, 7, 18006-18020.	0.8	11
750	Targeting cancer stem cells with p53 modulators. <i>Oncotarget</i> , 2016, 7, 45079-45093.	0.8	18
751	ER stress inducer tunicamycin suppresses the self-renewal of glioma-initiating cell partly through inhibiting Sox2 translation. <i>Oncotarget</i> , 2016, 7, 36395-36406.	0.8	15
752	Etoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits. <i>Oncotarget</i> , 2016, 7, 51138-51149.	0.8	21
753	Computational analyses for cancer biology based on exhaustive experimental backgrounds. , 2019, 2, 419-427.		1
754	Anti-Cancer Phytometabolites Targeting Cancer Stem Cells. <i>Current Genomics</i> , 2017, 18, 156-174.	0.7	25
755	Functional Polymorphism in the MSI1 Gene Promoter Confers a Decreased Risk of Lung Cancer in Chinese by Reducing MSI1 Expression. <i>Current Genomics</i> , 2018, 19, 375-383.	0.7	6
756	Colon cancer stem cells: implications in carcinogenesis. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1651.	3.0	57
757	Immunohistochemical Expression of Nanog and Its Relation with Clinicopathologic Characteristics in Breast Ductal Carcinoma. <i>Iranian Biomedical Journal</i> , 2019, 23, 184-9.	0.4	8
758	Immunohistochemical Expression of Nanog and Its Relation with Clinicopathologic Characteristics in Breast Ductal Carcinoma. <i>Iranian Biomedical Journal</i> , 2019, 23, 184-189.	0.4	9
759	Versatility of stem and progenitor cells and the instructive actions of cytokines on hematopoiesis. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 168-79.	2.7	40
760	Implication of stem cells in the biology and therapy of head and neck cancer. <i>GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery</i> , 2011, 10, Doc01.	0.8	5
761	Cancer Stem Cells: Plasticity Works against Therapy. <i>Acta Naturae</i> , 2015, 7, 46-55.	1.7	16
762	Radioresistance and Cancer Stem Cells: Survival of the Fittest. <i>Journal of Carcinogenesis & Mutagenesis</i> , 0, s1, .	0.3	10
763	The Cancer Stem Cell Conundrum in Multiple Myeloma. <i>Journal of Stem Cell Research & Therapy</i> , 2012, 02, .	0.3	3
764	Types of Human Stem Cells and Their Therapeutic Applications. <i>Stem Cell Discovery</i> , 2014, 04, 13-26.	0.5	3
765	Functional ion channels in stem cells. <i>World Journal of Stem Cells</i> , 2011, 3, 19.	1.3	49

#	ARTICLE	IF	CITATIONS
766	Aiming to immune elimination of ovarian cancer stem cells. <i>World Journal of Stem Cells</i> , 2013, 5, 149.	1.3	6
767	Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. <i>World Journal of Stem Cells</i> , 2016, 8, 316.	1.3	17
768	Pancreatic cancer diagnosis by free and exosomal miRNA. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2013, 4, 74.	0.5	67
769	Role of cancer stem cells in age-related rise in colorectal cancer. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2015, 6, 86.	0.5	4
770	Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2014, 33, 529-38.	4.9	25
771	Targeting Cancer Stem Cells with Defined Compounds and Drugs. <i>Journal of Cancer Research Updates</i> , 0, , .	0.3	3
772	Cancer Stem Cell: The Seed of Tumors?. <i>North American Journal of Medicine & Science</i> , 2009, 2, 1.	3.8	2
773	Cancer Stem Cells in the Origin and Transformation of Barrett's Esophagus: Current Knowledge and Areas of Uncertainty. <i>Immuno-gastroenterology</i> , 2013, 2, 9.	0.4	2
774	Cancer stem cells and addicted cancer cells. <i>Oncology Discovery</i> , 2013, 1, 7.	0.5	3
775	LY294002 Induces G0/G1 Cell Cycle Arrest and Apoptosis of Cancer Stem-like Cells from Human Osteosarcoma Via Down-regulation of PI3K Activity. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 3103-3107.	0.5	39
776	ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10814.	1.8	8
777	The Stem State in Cancer. , 2009, , 217-244.		0
778	Adrenocortical Stem and Progenitor Cells: Implications for Cancer. , 2009, , 285-304.		0
779	Regulation of Self-Renewing Divisions in Normal and Leukaemia Stem Cells. , 2010, , 109-125.		1
780	Epithelial Progenitor Cells of the Mammalian Lung. , 2010, , 125-154.		0
781	Ovarian Cancer Progenitor/Stem Cells: Therapeutic Potential. , 2011, , 223-244.		0
782	Cytokine Immunotherapy. , 2011, , 281-305.		0
783	An Overview on Animal Models of ALL. , 2011, , 105-115.		0

#	ARTICLE	IF	CITATIONS
784	Trivalent and Trispecific Antibody Derivatives for Cancer Therapy. , 2011, , 65-82.		0
785	The role of HIWI in stem cell maintenance and sarcomagenesis.. Journal of Clinical Oncology, 2011, 29, e20500-e20500.	0.8	1
786	Cancer Stem Cells: An Innovative Therapeutic Approach. , 2012, , 239-266.		0
787	Cancer Stem Cells: A Revisitation of the "Anaplasia" Concept. , 2012, , 1-16.		0
788	Cancer Stem Cells and the Microenvironment. , 2012, , 69-84.		0
789	Protein Therapeutics in Oncology. , 2012, , 109-144.		1
790	Translating Mammary Stem Cell and Cancer Stem Cell Biology to the Clinics. , 2012, , 433-450.		0
791	Stem Cells and Leukemia. , 2012, , 267-306.		0
792	Identification of Glioma Stem Cells: What is Already Known and How Far do We Still Need to Go? The Biomarkers Dilemma. Journal of Carcinogenesis & Mutagenesis, 2012, s1, .	0.3	1
793	An exciting time to launch the World Journal of Hematology. World Journal of Hematology, 2012, 1, 1.	0.1	0
794	Targeting Human Cancer Stem Cells with Monoclonal Antibodies. Journal of Clinical & Cellular Immunology, 2012, 01, .	1.5	0
795	Regulation of Hematopoietic Stem Cell Fate: Self-Renewal, Quiescence and Survival. , 0, , .		0
796	Basic Issues on Cancer Stem Cells-Concept, In vitro Models and Therapeutic Implications. Niche Journal, 2012, 1, 17-20.	0.4	0
797	Defining Multiple Myeloma as a Target for DNA Vaccines. , 2013, , 73-110.		0
798	An Introduction to Proliferation and Migration of Stem and Cancer Cells. , 2013, , 3-12.		0
799	Mechanisms of Metastasis. , 2013, , 435-458.		5
800	Heterogeneity of Cancers and Its Implication for Targeted Drug Delivery. , 2013, , 337-362.		0
801	Systems Modeling of Proliferation Mechanisms in Childhood Acute Lymphoblastic Leukemia. , 2013, , 227-256.		0

#	ARTICLE	IF	CITATIONS
802	Therapy Resistance in Prostate Cancer: A Stem Cell Perspective. <i>Pancreatic Islet Biology</i> , 2013, , 279-300.	0.1	0
803	Targeting the Prostate Stem Cell for Chemoprevention. , 2013, , 127-148.		0
804	Proliferation and Regeneration. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2013, , 31-52.	0.3	1
808	Colorectal Cancer Stem Cells. , 2015, , 227-245.		0
809	Epigenetic of Retinoic Acid Receptor β 2 Gene in Breast Cancer. , 2015, , 311-362.		0
812	Cancer: Risk Aspects and Measures of Their Control. <i>IOSR Journal of Dental and Medical Sciences</i> , 2016, 15, 94-97.	0.0	2
813	Identification of a stem cell surface marker of hypopharyngeal cancer and analysis of its function. <i>Japanese Journal of Head and Neck Cancer</i> , 2017, 43, 339-344.	0.0	0
814	Axl and Its Mediated Signaling Axis in Cancer. , 2017, , 39-60.		0
816	Notch Signaling in the Normal Intestine and Intestinal Cancer. , 2018, , 333-352.		0
819	CHANGES IN STROMAL PROGENITOR CELLS DERIVED FROM BONE MARROW IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA AT THE ONSET OF THE DISEASE AND DURING TREATMENT. <i>Gematologiya i Transfuziologiya</i> , 2019, 64, 424-435.	0.1	1
821	CELL SURFACE MOLECULAR MARKERS FOR IDENTIFICATION OF CANCER STEM CELL POPULATIONS (SYSTEMATIC REVIEW). <i>Voprosy Onkologii</i> , 2020, 66, 336-345.	0.1	0
823	Metabolic Changes and Their Characterization. , 2020, , 35-70.		1
824	CaMKII β regulates the viability and self-renewal of acute myeloid leukaemia stem-like cells by the Alox5/NF κ B pathway. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 699-706.	0.7	6
825	Convergence of oncogenic cooperation at single-cell and single-gene levels drives leukemic transformation. <i>Nature Communications</i> , 2021, 12, 6323.	5.8	10
826	Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 5543.	1.7	9
827	MicroRNA-145 promotes the apoptosis of leukemic stem cells and enhances drug-resistant K562/ADM cell sensitivity to adriamycin via the regulation of ABCE1. <i>International Journal of Molecular Medicine</i> , 2020, 46, 1289-1300.	1.8	4
828	Natural product-based therapeutics for the treatment of cancer stem cells: a patent review (2010 -) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.4	4
830	Leukemia Stem Cells: Concept and Implications. <i>Methods in Molecular Biology</i> , 2021, 2185, 25-37.	0.4	2

#	ARTICLE	IF	CITATIONS
831	Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 2190-2206.	0.9	12
833	Expanding roles of ZEB factors in tumorigenesis and tumor progression. <i>American Journal of Cancer Research</i> , 2011, 1, 897-912.	1.4	90
834	The regulation of telomerase in oncogenesis. <i>Acta Naturae</i> , 2009, 1, 51-67.	1.7	5
835	On the origin and destination of cancer stem cells: a conceptual evaluation. <i>American Journal of Cancer Research</i> , 2013, 3, 107-16.	1.4	14
838	Cancer Stem Cells: Plasticity Works against Therapy. <i>Acta Naturae</i> , 2015, 7, 46-55.	1.7	7
839	Reciprocal Interactions of Leukemic Cells with Bone Marrow Stromal Cells Promote Enrichment of Leukemic Stem Cell Compartments in Response to Curcumin and Daunorubicin. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 831-840.	0.5	14
841	Isolation and characterization of cancer stem cells derived from human glioblastoma. <i>American Journal of Cancer Research</i> , 2021, 11, 441-457.	1.4	3
843	Theranostics of Hematologic Disorders. , 2022, , 359-432.		0
845	Advancement in Cancer Stem Cell Biology and Precision Medicine—Review Article Head and Neck Cancer Stem Cell Plasticity and the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 660210.	1.8	9
846	Identification, Culture and Targeting of Cancer Stem Cells. <i>Life</i> , 2022, 12, 184.	1.1	11
847	Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy. <i>Developmental Cell</i> , 2022, 57, 32-46.e8.	3.1	71
849	Lipid metabolism of cancer stem cells (Review). <i>Oncology Letters</i> , 2022, 23, 119.	0.8	18
850	Differentiation therapy for myeloid malignancies: beyond cytotoxicity. <i>Blood Cancer Journal</i> , 2021, 11, 193.	2.8	31
851	Molecular signaling and its role in drug resistance in hepatocellular carcinomas. , 2022, , 209-225.		0
852	Oncogenes and the Origins of Leukemias. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2293.	1.8	4
853	Adapalene Inhibits Prostate Cancer Cell Proliferation In Vitro and In Vivo by Inducing DNA Damage, S-phase Cell Cycle Arrest, and Apoptosis. <i>Frontiers in Pharmacology</i> , 2022, 13, 801624.	1.6	6
854	Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3412.	1.8	18
855	Targeting cancer-associated glycans as a therapeutic strategy in leukemia. <i>International Journal of Transgender Health</i> , 2022, 15, 378-433.	1.1	2

#	ARTICLE	IF	CITATIONS
856	In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. <i>Leukemia</i> , 2022, 36, 1313-1323.	3.3	11
857	KRAB-ZFPs and cancer stem cells identity. <i>Genes and Diseases</i> , 2023, 10, 1820-1832.	1.5	3
858	Effect of aberrant DNA methylation on cancer stem cell properties. <i>Experimental and Molecular Pathology</i> , 2022, 125, 104757.	0.9	17
859	Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model. <i>Cancers</i> , 2022, 14, 1882.	1.7	6
860	Overexpression of the GR Riborepressor LncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL. <i>Cancers</i> , 2021, 13, 6064.	1.7	5
861	Large-scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML. <i>International Journal of Cancer</i> , 2022, 150, 1455-1470.	2.3	5
862	A Fokker-Planck feedback control framework for optimal personalized therapies in colon cancer-induced angiogenesis. <i>Journal of Mathematical Biology</i> , 2022, 84, 23.	0.8	4
867	Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 344-367.	0.9	4
868	Antagonizing RAR β Drives Necroptosis of Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4814.	1.8	5
869	Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells. <i>Stem Cell Research and Therapy</i> , 2022, 13, 181.	2.4	33
870	The Social Norm of Hematopoietic Stem Cells and Dysregulation in Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5063.	1.8	3
871	Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 113054.	2.5	91
872	Brusatol Inhibits Proliferation and Metastasis of Colorectal Cancer by Targeting and Reversing the RhoA/ROCK1 Pathway. <i>BioMed Research International</i> , 2022, 2022, 1-13.	0.9	10
873	Mitochondrial Fusion Supports Proliferation of Leukemia-Initiating Cells Through mTORC1 in Patient-Derived Xenograft Models. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
874	A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. <i>Nature Medicine</i> , 2022, 28, 1212-1223.	15.2	104
875	The Emerging Roles of Aldehyde Dehydrogenase in Acute Myeloid Leukemia and its Therapeutic Potential. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, .	0.9	0
876	Fluorescence Detection of Cancer Stem Cell Markers Using a Sensitive Nano-Aptamer Sensor. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
877	New Insights into TRP Ion Channels in Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7766.	1.8	4

#	ARTICLE	IF	CITATIONS
878	Large-Scale <i>In Vitro</i> and <i>In Vivo</i> CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 4033-4044.	3.2	4
879	Direct cell-cell interaction regulates division of stem cells from PC-3 human prostate cancer cell line. <i>Biochemical and Biophysical Research Communications</i> , 2022, 631, 25-31.	1.0	1
880	Targeting triple-negative breast cancers using nanomedicine. , 2022, , 199-255.		1
881	Cellular hierarchies predict drug response in acute myeloid leukemia. <i>Cancer Cell</i> , 2022, 40, 917-919.	7.7	0
882	Lessons to cancer from studies of leukemia and hematopoiesis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
883	A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2023, 13, 332-347.	7.7	16
884	MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway. <i>Oncotarget</i> , 2022, 13, 1217-1236.	0.8	2
885	Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2023, 29, 134-142.	3.2	9
886	Elevated expression of LGR5 and WNT signalling factors in neuroblastoma cells with acquired drug resistance.. <i>Cancer Investigation</i> , 0, , 1-12.	0.6	2
887	Highly efficient Runx1 enhancer eR1-mediated genetic engineering for fetal, child and adult hematopoietic stem cells. <i>Gene</i> , 2023, 851, 147049.	1.0	1
888	Hematopoietic and Chronic Myeloid Leukemia Stem Cells: Multi-Stability versus Lineage Restriction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13570.	1.8	8
889	Expression of kinesin family member C1 in pancreatic ductal adenocarcinoma affects tumor progression and stemness. <i>Pathology Research and Practice</i> , 2023, 241, 154277.	1.0	3
890	Cancer Stem Cells: Biology and Therapeutic Implications. <i>Archives of Medical Research</i> , 2022, 53, 770-784.	1.5	7
891	The Transcription Factors Zeb1 and Snail Induce Cell Malignancy and Cancer Stem Cell Phenotype in Prostate Cells, Increasing Androgen Synthesis Capacity and Therapy Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 51-64.	0.8	2
892	The Concept of Cancer Stem Cells: Elaborating on ALDH1B1 as an Emerging Marker of Cancer Progression. <i>Life</i> , 2023, 13, 197.	1.1	3
893	Targeting the Retinoic Acid Pathway to Eradicate Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2373.	1.8	5
894	Functions and regulatory mechanisms of resting hematopoietic stem cells: a promising targeted therapeutic strategy. <i>Stem Cell Research and Therapy</i> , 2023, 14, .	2.4	0
895	Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2. <i>Phytomedicine</i> , 2023, 114, 154764.	2.3	7

#	ARTICLE	IF	CITATIONS
896	MicroRNA mediated gene regulatory circuits leads to machine learning based preliminary detection of acute myeloid leukemia. <i>Computational Biology and Chemistry</i> , 2023, 104, 107859.	1.1	1
897	Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives. <i>Seminars in Cancer Biology</i> , 2023, 92, 84-101.	4.3	2
898	Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia. <i>Leukemia</i> , 2023, 37, 765-775.	3.3	7
899	NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer. <i>Genes</i> , 2023, 14, 607.	1.0	0
900	Phytochemical-based nanodrugs going beyond the state-of-the-art in cancer management—Targeting cancer stem cells in the framework of predictive, preventive, personalized medicine. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	5
901	Advancing biomarker development for diagnostics and therapeutics using solid tumour cancer stem cell models. <i>Tumori</i> , 2024, 110, 10-24.	0.6	0
902	Retinoic acid receptor regulation of decision-making for cell differentiation. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	4
910	Detection and Isolation of Cancer Stem Cells. , 2023, , 45-69.		0
913	A non-coding m6A reader promotes leukaemia. <i>Nature Cell Biology</i> , 0, , .	4.6	0
916	Chemical approaches to stem cell and signaling pathways for therapeutics. , 2024, , 309-321.		0